



PCT/GB 2003 / 001578



INVESTOR IN PEOPLE	
REC'D 20 JUN 2003	
WIPO	PCT

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation and Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents held on the international application filed on 28 March 2002 at the Patent Cooperation Treaty at the UK Receiving Office. The application was allocated the number PCT/GB02/01578

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or the inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Date: 21 May 2003

BEST AVAILABLE COPY

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No. **PCT/GB 02 / 0 1 5 7 8**

International Filing Date **28 MARCH 2002**
28 - 03 - 02

United Kingdom Patent Office
Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference
(if desired) (12 characters maximum) **HL78629/012**

Box No. I TITLE OF INVENTION

Sapogenin Derivatives, their Synthesis and Use, and Methods based upon their use.

Box No. II APPLICANT

☐ This person is also inventor

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

PHYTOTECH LIMITED
Corpus Christi House, 9 West Street, Godmanchester
Cambridgeshire PE18 8HG (GB)

Telephone No.
01480 437697

Facsimile No.
01480 41709

Teleprinter No.

Applicant's registration No. with the Office

State (that is, country) of nationality:
United Kingdom

State (that is, country) of residence:
United Kingdom

This person is applicant for the purposes of:

☐ all designated States

☒ all designated States except the United States of America

☐ the United States of America only

☐ the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

BARRACLOUGH, Paul
27 Sevington Park, Loose, Maidstone, Kent ME15 9SB
(GB)

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:
United Kingdom

State (that is, country) of residence:
United Kingdom

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☒ the United States of America only

☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:

☒ agent

☐ common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

BROWN, David Leslie et al
HASELTINE LAKE & CO
Imperial House, 15-19 Kingsway, London WC2B 6UD (GB)

Telephone No.
+44 20 7420 0500

Facsimile No.
+44 20 7420 0505

Teleprinter No.

Agent's registration No. with the Office

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Box No. V DESIGNATION STATES Mark the applicable check-boxes below; at least one must be marked.

The following designations are hereby made under Rule 4.9(a):

Regional Patent

- ☒ **AP ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, MZ Mozambique, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZM Zambia, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT (if other kind of protection or treatment desired, specify on dotted line)
- ☒ **EA Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP European Patent:** AT Austria, BE Belgium, CH & LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, TR Turkey, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GQ Equatorial Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

National Patent (if other kind of protection or treatment desired, specify on dotted line):

- | | | |
|---|--|---|
| <input checked="" type="checkbox"/> AE United Arab Emirates | <input checked="" type="checkbox"/> GM Gambia | <input checked="" type="checkbox"/> NZ New Zealand |
| <input checked="" type="checkbox"/> AG Antigua and Barbuda | <input checked="" type="checkbox"/> HR Croatia | <input checked="" type="checkbox"/> OM Oman |
| <input checked="" type="checkbox"/> AL Albania | <input checked="" type="checkbox"/> HU Hungary | <input checked="" type="checkbox"/> PH Philippines |
| <input checked="" type="checkbox"/> AM Armenia | <input checked="" type="checkbox"/> ID Indonesia | <input checked="" type="checkbox"/> PL Poland |
| <input checked="" type="checkbox"/> AT Austria | <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> AU Australia | <input checked="" type="checkbox"/> IN India | <input checked="" type="checkbox"/> RO Romania |
| <input checked="" type="checkbox"/> AZ Azerbaijan | <input checked="" type="checkbox"/> IS Iceland | <input checked="" type="checkbox"/> RU Russian Federation |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina | <input checked="" type="checkbox"/> JP Japan | |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> KE Kenya | <input checked="" type="checkbox"/> SD Sudan |
| <input checked="" type="checkbox"/> BG Bulgaria | <input checked="" type="checkbox"/> KG Kyrgyzstan | <input checked="" type="checkbox"/> SE Sweden |
| <input checked="" type="checkbox"/> BR Brazil | <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea | <input checked="" type="checkbox"/> SG Singapore |
| <input checked="" type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> KR Republic of Korea | <input checked="" type="checkbox"/> SI Slovenia |
| <input checked="" type="checkbox"/> BZ Belize | <input checked="" type="checkbox"/> KZ Kazakhstan | <input checked="" type="checkbox"/> SK Slovakia |
| <input checked="" type="checkbox"/> CA Canada | <input checked="" type="checkbox"/> LC Saint Lucia | <input checked="" type="checkbox"/> SL Sierra Leone |
| <input checked="" type="checkbox"/> CH & LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> LK Sri Lanka | <input checked="" type="checkbox"/> TJ Tajikistan |
| <input checked="" type="checkbox"/> CN China | <input checked="" type="checkbox"/> LR Liberia | <input checked="" type="checkbox"/> TM Turkmenistan |
| <input checked="" type="checkbox"/> CO Colombia | <input checked="" type="checkbox"/> LS Lesotho | <input checked="" type="checkbox"/> TN Tunisia |
| <input checked="" type="checkbox"/> CR Costa Rica | <input checked="" type="checkbox"/> LT Lithuania | <input checked="" type="checkbox"/> TR Turkey |
| <input checked="" type="checkbox"/> CU Cuba | <input checked="" type="checkbox"/> LU Luxembourg | <input checked="" type="checkbox"/> TT Trinidad and Tobago |
| <input checked="" type="checkbox"/> CZ Czech Republic | <input checked="" type="checkbox"/> LV Latvia | |
| <input checked="" type="checkbox"/> DE Germany | <input checked="" type="checkbox"/> MA Morocco | <input checked="" type="checkbox"/> TZ United Republic of Tanzania |
| <input checked="" type="checkbox"/> DK Denmark | <input checked="" type="checkbox"/> MD Republic of Moldova | <input checked="" type="checkbox"/> UA Ukraine |
| <input checked="" type="checkbox"/> DM Dominica | <input checked="" type="checkbox"/> MG Madagascar | <input checked="" type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> DZ Algeria | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia | <input checked="" type="checkbox"/> US United States of America |
| <input checked="" type="checkbox"/> EC Ecuador | <input checked="" type="checkbox"/> MN Mongolia | |
| <input checked="" type="checkbox"/> EE Estonia | <input checked="" type="checkbox"/> MW Malawi | <input checked="" type="checkbox"/> UZ Uzbekistan |
| <input checked="" type="checkbox"/> ES Spain | <input checked="" type="checkbox"/> MX Mexico | <input checked="" type="checkbox"/> VN Viet Nam |
| <input checked="" type="checkbox"/> FI Finland | <input checked="" type="checkbox"/> MZ Mozambique | <input checked="" type="checkbox"/> YU Yugoslavia |
| <input checked="" type="checkbox"/> GB United Kingdom | <input checked="" type="checkbox"/> NO Norway | <input checked="" type="checkbox"/> ZA South Africa |
| <input checked="" type="checkbox"/> GD Grenada | | <input checked="" type="checkbox"/> ZM Zambia |
| <input checked="" type="checkbox"/> GE Georgia | | <input checked="" type="checkbox"/> ZW Zimbabwe |
| <input checked="" type="checkbox"/> GH Ghana | | |

Check-boxes below reserved for designating States which have become party to the PCT after issuance of this sheet:

<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation (including fees) must reach the receiving Office within the 15-month time limit.)

Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

HANSON, Jim
13 Ingram Road, Steyning
West Sussex BN44 3PF (GB)

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:

United Kingdom

State (that is, country) of residence:

United Kingdom

This person is applicant for the purposes of:

☐ all designated States☐ all designated States except the United States of America☒ the United States of America only☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

GUNNING, Phil
16 Sladwell Close, Grantchester
Cams. CB3 9NP (GB)

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:

United Kingdom

State (that is, country) of residence:

United Kingdom

This person is applicant for the purposes of:

☐ all designated States☐ all designated States except the United States of America☒ the United States of America only☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

REES, Daryl
4 Hazels Hall, Everton Road,
Sandy SG19 2DD (GB)

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:

United Kingdom

State (that is, country) of residence:

United Kingdom

This person is applicant for the purposes of:

☐ all designated States☐ all designated States except the United States of America☒ the United States of America only☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

XIA, Zongqin
Flat 403, Block 8, 1 Jian-De Road,
Shanghai 200025 (CN)

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:

China

State (that is, country) of residence:

China

This person is applicant for the purposes of:

☐ all designated States☐ all designated States except the United States of America☒ the United States of America only☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on another continuation sheet.

Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S) <i>If none of the following sub-boxes is used, this sheet should not be included in the request.</i>	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i> HU, Yaer Flat 1209, Block 1, Lane 357, Ma-Dang Road, Shanghai 200025 (CN)	This person is: <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only <i>(If this check-box is marked, do not fill in below.)</i> Applicant's registration No. with the Office
State <i>(that is, country)</i> of nationality: China	State <i>(that is, country)</i> of residence: China
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i> 	This person is: <input type="checkbox"/> applicant only <input type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only <i>(If this check-box is marked, do not fill in below.)</i> Applicant's registration No. with the Office
State <i>(that is, country)</i> of nationality:	State <i>(that is, country)</i> of residence:
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i> 	This person is: <input type="checkbox"/> applicant only <input type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only <i>(If this check-box is marked, do not fill in below.)</i> Applicant's registration No. with the Office
State <i>(that is, country)</i> of nationality:	State <i>(that is, country)</i> of residence:
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i> 	This person is: <input type="checkbox"/> applicant only <input type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only <i>(If this check-box is marked, do not fill in below.)</i> Applicant's registration No. with the Office
State <i>(that is, country)</i> of nationality:	State <i>(that is, country)</i> of residence:
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
Name and address: <i>(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i> 	This person is: <input type="checkbox"/> applicant only <input type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only <i>(If this check-box is marked, do not fill in below.)</i> Applicant's registration No. with the Office
State <i>(that is, country)</i> of nationality:	State <i>(that is, country)</i> of residence:
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
<input type="checkbox"/> Further applicants and/or (further) inventors are indicated on another continuation sheet.	

Box No. VI PRIORITY CLAIM

The priority of the following earlier application(s) is hereby claimed:

Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country	regional application:* regional Office	international application: receiving Office
item (1) 28/03/2001 28 MARCH 2001	0107822.9	GB		
item (2)				
item (3)				
item (4)				
item (5)				

☐ Further priority claims are indicated in the Supplemental Box.

The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of this international application is the receiving Office) identified above as:

☐ all items ☒ item (1) ☐ item (2) ☐ item (3) ☐ item (4) ☐ item (5) ☐ other, see Supplemental Box

* Where the earlier application is an ARIPO application, indicate at least one country party to the Paris Convention for the Protection of Industrial Property or one Member of the World Trade Organization for which that earlier application was filed (Rule 4.10(b)(ii)):

.....

Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):

ISA /

Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):

Date (day/month/year)

Number

Country (or regional Office)

Box No. VIII DECLARATIONS

The following declarations are contained in Boxes Nos. VIII (i) to (v) (mark the applicable check-boxes below and indicate in the right column the number of each type of declaration):

Number of
declarations

- | | | |
|---|--|---|
| <input type="checkbox"/> Box No. VIII (i) | Declaration as to the identity of the inventor | : |
| <input type="checkbox"/> Box No. VIII (ii) | Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent | : |
| <input type="checkbox"/> Box No. VIII (iii) | Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application | : |
| <input type="checkbox"/> Box No. VIII (iv) | Declaration of inventorship (only for the purposes of the designation of the United States of America) | : |
| <input type="checkbox"/> Box No. VIII (v) | Declaration as to non-prejudicial disclosures or exceptions to lack of novelty | : |

See Notes to the request form

Box No. IX CHECK LIST; LANGUAGE OF FILING

This international application contains:

(a) the following number of sheets in paper form:

request (including declaration sheets) : 6
 description (excluding sequence listing part) : 37
 claims : 11
 abstract : 1
 drawings : 3

Sub-total number of sheets : 58

sequence listing part of description (actual number of sheets if filed in paper form, whether or not also filed in computer readable form; see (b) below) : _____

Total number of sheets : 58

(b) sequence listing part of description filed in computer readable form

(i) ☐ only (under Section 801(a)(i))(ii) ☐ in addition to being filed in paper form (under Section 801(a)(ii))

Type and number of carriers (diskette, CD-ROM, CD-R or other) on which the sequence listing part is contained (additional copies to be indicated under item 9(ii), in right column):

This international application is accompanied by the following item(s) (mark the applicable check-boxes below and indicate in right column the number of each item):

1. ☐ fee calculation sheet
2. ☐ original separate power of attorney
3. ☐ original general power of attorney
4. ☐ copy of general power of attorney; reference number, if any: _____
5. ☐ statement explaining lack of signature
6. ☐ priority document(s) identified in Box No. VI as item(s): _____
7. ☐ translation of international application into (language): _____
8. ☐ separate indications concerning deposited microorganism or other biological material
9. ☐ sequence listing in computer readable form (indicate also type and number of carriers (diskette, CD-ROM, CD-R or other))
 - (i) ☐ copy submitted for the purposes of international search under Rule 13ter only (and not as part of the international application)
 - (ii) ☐ (only where check-box (b)(i) or (b)(ii) is marked in left column) additional copies including, where applicable, the copy for the purposes of international search under Rule 13ter
 - (iii) ☐ together with relevant statement as to the identity of the copy or copies with the sequence listing part mentioned in left column
10. ☒ other (specify): P23/77

Number of items

Figure of the drawings which should accompany the abstract:

Language of filing of the international application: English

Box No. X SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).



NASH, David Allan

For receiving Office use only

1. Date of actual receipt of the purported international application:

28 MARCH 2002

28-03-02

3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:

4. Date of timely receipt of the required corrections under PCT Article 11(2):

5. International Searching Authority (if two or more are competent): ISA /

6. ☒ Transmittal of search copy delayed until search fee is paid

2. Drawings:

☒ received:☐ not received:

For International Bureau use only

Date of receipt of the record copy by the International Bureau:

**SAPOGENIN DERIVATIVES. THEIR SYNTHESIS AND USE, AND METHODS
BASED UPON THEIR USE**

Field of the Invention

5 The present invention relates to sapogenins and their derivatives, their synthesis and use, and methods based upon their use.

10 The use of the sapogenins and their derivatives is in the treatment of cognitive dysfunction, non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, and receptor loss. In a further aspect, the invention relates to compositions for use in such treatments.

Background of the Invention

15 Cognitive dysfunction is a characteristic of dementia conditions and syndromes, such as Alzheimer's disease (AD), senile dementia of the Alzheimer's type (SDAT), Lewi body dementia and vascular dementia. A lesser degree of cognitive dysfunction is also a characteristic of certain non-dementia conditions and syndromes, such as mild cognitive impairment (MCI), age-associated memory impairment (AAMI) and autism.


20 Non-cognitive neurodegeneration (i.e. neurodegeneration in the absence of cognitive dysfunction) and non-cognitive neuromuscular degeneration (i.e. neuromuscular degeneration in the absence of cognitive dysfunction) is a characteristic of conditions and syndromes such as Parkinson's disease, muscular dystrophy including facioscapulohumeral muscular
25 dystrophy (FSH), Duchenne muscular dystrophy, Becker muscular dystrophy and Bruce's muscular dystrophy, Fuchs' dystrophy, myotonic dystrophy, corneal dystrophy, reflex sympathetic dystrophy syndrome (RSDSA), neurovascular dystrophy, myasthenia gravis, Lambert Eaton disease, Huntington's disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis.

30 Receptor loss – particularly loss of nicotinic and/or muscarinic receptors and/or dopamine receptors and/or adrenoceptors – is a characteristic of some or all of the above conditions and syndromes. Said receptor loss in the absence of cognitive, neural and neuromuscular impairment is also a characteristic of conditions and syndromes such as postural hypotension,
35 chronic fatigue syndrome, asthma, susceptibility to heart failure and macular degeneration.

The above conditions and syndromes are grave and growing problems in all societies where, because of an increase in life expectancy and control of adventitious disease, the demographic profile is increasingly extending towards a more aged population. Agents which can treat, or help in the management or prevention of such disorders, are urgently required.

5

WO-A-01/23406, the disclosure of which is incorporated herein by reference, claims, amongst other compounds, sapogenin derivatives of general formula (I):



10

and their stereoisomers and racemic mixtures, their pharmaceutically acceptable pro-drugs and salts, wherein:

15

-R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₁₀, are, independently of each other, either H, OH, =O, and OR where R = optionally substituted alkyl, optionally substituted acyl, optionally substituted carbamoyl, alkoxycarbonyl;

20

- R₉, R₁₂, R₁₁, R₁₃ can be either a H, OH, OR where R = optionally substituted alkyl, optionally substituted acyl, optionally substituted carbamoyl, alkoxycarbonyl;

- R₁₄ = optionally substituted alkyl group,

..... represents an optional double bond,

but excluding where simultaneously:

25

-R₁=R₂=R₄=R₅=R₆=R₇=R₈=R₁₀=R₁₁=R₉=R₁₂=R₁₃=H,

-R₃=βOH,

-R₁₄=CH₃

-the methyl group at C22 is α,

-the C20 is α, and there is a S configuration at C25;

and the use of these compounds as agents for increasing the muscarinic receptor number or enhancing the function of muscarinic receptors in a human or non-human animal, more particularly to treat cognitive dysfunction in diseases, more particularly still for the treatment of cognitive dysfunction in a patient suffering from a disease selected from AD, SDAT,
 5 Parkinson's disease, Lewi body dementia, autism, Myasthenia Gravis, Lambert Eaton disease, postural hypotension, chronic fatigue syndrome and diseases and problem associated with ageing.

10 According to the definitions contained in the description of WO-A-01/23406, in the variable groups of the above formula (I):

"Acyl" means an H-CO- or Alkyl-CO- group wherein the alkyl group is as defined below. Preferred acyls contain a lower alkyl. Exemplary acyl groups include formyl, acetyl,
 15 propanoyl, 2-methylpropanoyl, butanoyl and palmitoyl;

"Alkyl" means an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups have 1 to about 12 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as
 20 methyl, ethyl or propyl are attached to a linear alkyl chain. "Lower alkyl" means about 1 to about 4 carbon atoms in the chain which may be straight or branched. Exemplary alkyl groups include methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *t*-butyl, *n*-pentyl, 3-pentyl;

"Optionally substituted" means that the said group may be substituted with one or more
 25 substituents which may be the same or different, and include halo, alkyl, cycloalkyl, hydroxy, alkoxy, amino, acylamino, aryl, aroylamino, carboxy, alkoxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, optionally substituted carbamoyl;

"Pharmaceutically acceptable" means it is, within the scope of sound medical and veterinary
 30 judgement, suitable for use in contact with the cells of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. "Pharmaceutically acceptable prodrugs" means those prodrugs of the compounds which are, within the scope of sound medical and veterinary judgment,
 35 suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds. The term "prodrug" means compounds that are rapidly

transformed *in vivo* to yield the parent compound of the above formula, for example by hydrolysis in blood. Functional groups which may be rapidly transformed, by metabolic cleavage, *in vivo* form a class of groups reactive with the carboxyl group. Because of the ease with which the metabolically cleavable groups of the compounds are cleaved *in vivo*, the compounds bearing such groups act as pro-drugs. A thorough discussion of prodrugs is provided in the following: Design of Prodrugs, H. Bundgaard, ed., Elsevier, 1985; Methods in Enzymology, K. Widder et al, Ed., Academic Press, 42, p.309-396, 1985; A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard, ed., Chapter 5; Design and Applications of Prodrugs p.113-191, 1991; Advanced Drug Delivery Reviews, H. Bundgaard, 8, p.1-38, 1992; Journal of Pharmaceutical Sciences, 77, p. 285, 1988; Chem. Pharm. Bull., N. Nakeya et al, 32, p. 692, 1984; Pro-drugs as Novel Delivery Systems, T. Higuchi and V. Stella, Vol. 14 of the A.C.S. Symposium Series, and Bioreversible Carriers in Drug Design, Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press, 1987, which are incorporated herein by reference;

“Pharmaceutically acceptable salts” means the relatively non-toxic, inorganic and organic acid addition salts, and base addition salts, of the compounds. These salts can be prepared *in situ* during the final isolation and purification of the compounds. In particular, acid addition salts can be prepared by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. See, for example S. M. Berge, et al., Pharmaceutical Salts, J. Pharm. Sci., 66: p.1-19 (1977) which is incorporated herein by reference. Base addition salts can also be prepared by separately reacting the purified compound in its acid form with a suitable organic or inorganic base and isolating the salt thus formed. Base addition salts include pharmaceutically acceptable metal and amine salts.

According to the description in WO-A-01/23406, the effectiveness of the sapogenins of general formula I, including their stereoisomers and racemic mixtures, their pharmaceutically acceptable pro-drugs and salts is attributed at least in part to an activity of the compounds to normalise receptor number, i.e. to prevent decline in receptor number with time and also to restore receptor number from a depressed number to normal levels (page 20, lines.6 to 9).

DE-A-4303214, the disclosure of which is incorporated herein by reference, describes the use of a very wide range of saponins and sapogenins in the treatment of a wide range of viral diseases, but with no data that would allow one skilled in the art to select a preferred compound for any particular viral disease. Although Alzheimer's disease and Parkinson's

disease are mentioned, these conditions are known to be of non-viral origin, with the result that no relevant teaching can be discerned in the document.

5 WO-A-99/16786 (published 8 April 1999), the disclosure of which is incorporated herein by reference, describes the use of natural saponins for the treatment of dementia. Saponins tend to be water-soluble, whereas sapogenins are lipid-soluble and therefore saponins are less effective in crossing the blood-brain barrier.

10 Chinese Patent Application No. CN-A-1096031, the disclosure of which is incorporated herein by reference, describes the use of the spirostane sapogenin, sarsasapogenin, in the two-way regulation of β -adrenergic and M-cholinergic receptors. No specific pharmaceutical activity is suggested. However, in "Synthesis and Applications of Isotopically Labelled Compounds", 1998, pages 315-320, Yi et al describe the use of sarsasapogenin in the treatment of senile dementia.


15 In the cases of Parkinson's disease, myasthenia gravis, Lambert Eaton disease, postural hypotension and chronic fatigue syndrome, however, cognitive dysfunction is not a primary symptom, although it may be present as one of a number of possible secondary symptoms. Moreover, these conditions are not viral diseases or dementias. Many of these disorders are
20 so-called "spectrum" disorders, in which a wide range of combinations of symptoms, in a wide range of relative severities, present themselves. Therefore, in many instances, a treatment for cognitive dysfunction (e.g. dementia) is not necessary.

The present invention is based upon our finding that certain sapogenins and their derivatives,
25 including compounds from within the formula I as defined in WO-A-01/23406, have a surprising activity against non-cognitive neurodegeneration and non-cognitive neuromuscular degeneration, as well as against receptor loss in the absence of cognitive, neural and neuromuscular impairment. This finding enables improved treatment of certain non-viral spectrum and non-spectrum disorders in which cognitive dysfunction is not a primary
30 symptom, such as, for example, Parkinson's disease, muscular dystrophy including facioscapulohumeral muscular dystrophy (FSH), Duchenne muscular dystrophy, Becker muscular dystrophy and Bruce's muscular dystrophy, Fuchs' dystrophy, myotonic dystrophy, corneal dystrophy, reflex sympathetic dystrophy syndrome (RSDSA), neurovascular dystrophy, myasthenia gravis, Lambert Eaton disease, Huntington's disease, amyotrophic
35 lateral sclerosis (ALS), multiple sclerosis, postural hypotension, chronic fatigue syndrome, asthma, susceptibility to heart failure, and macular degeneration.

In addition, we have found that certain of the compounds have activity against cognitive dysfunction, which was not previously disclosed.

Brief Description of the Invention

According to one aspect of the present invention, there is provided the use of compounds of the general formula II:



wherein the group R is selected from hydrogen; alkylcarbonyl; or alkoxy carbonyl; wherein any alkyl group is optionally substituted with aryl, amino, mono- or di-alkyl-amino, a carboxylic acid residue (-COOH), or any combination thereof;

(including all stereoisomers and racemic mixtures thereof), and their pharmaceutically acceptable salts,

in the treatment or prevention of, or in the preparation of compositions (e.g. pharmaceutical compositions, foodstuffs, food supplements and beverages) for the treatment or prevention of, (i) non-cognitive neurodegeneration, (ii) non-cognitive neuromuscular degeneration, or (iii) receptor loss in the absence of cognitive, neural and neuromuscular impairment, in human and non-human animals suffering therefrom or susceptible thereto.

Most particularly, the said treatment may be applied to human and non-human animals suffering from any of: Parkinson's disease, muscular dystrophy including facioscapulohumeral muscular dystrophy (FSH), Duchenne muscular dystrophy, Becker muscular dystrophy and Bruce's muscular dystrophy, Fuchs' dystrophy, myotonic dystrophy, corneal dystrophy, reflex sympathetic dystrophy syndrome (RSDSA), neurovascular dystrophy, myasthenia gravis, Lambert Eaton disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, postural hypotension, chronic fatigue syndrome, asthma, susceptibility to heart failure, and macular degeneration.

According to a further aspect of the invention, there is provided the use of the compounds of formula II wherein the group R is selected from hydrogen; alkylcarbonyl; or alkoxycarbonyl; wherein any alkyl group is optionally substituted with aryl, amino, mono-alkyl-amino, di-alkyl-amino, a carboxylic acid residue (-COOH), or any combination thereof; provided that:

R is not hydrogen or unsubstituted acetyl unless simultaneously the stereochemistry of C3 is α and of C25 is S,

R is not unsubstituted ethoxycarbonyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is R; and

R is not succinyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is S or the stereochemistry of C3 is R(α) and of C25 is R;

(including, subject to the provisos set out above, all stereoisomers and racemic mixtures thereof), and their pharmaceutically acceptable salts,

in the treatment or prevention of, or in the preparation of compositions (e.g. pharmaceutical compositions, foodstuffs, food supplements and beverages) for the treatment or prevention of, (i) cognitive dysfunction, (ii) non-cognitive neurodegeneration, (iii) non-cognitive neuromuscular degeneration, or (iv) receptor loss in the absence of cognitive, neural and neuromuscular impairment, in human and non-human animals suffering therefrom or susceptible thereto.

In one aspect the C₂₅ methyl group is in the S configuration; these compounds of the invention are sarsasapogenin and episarsasapogenin or derivatives thereof. In another aspect, the C₂₅ methyl group is in the R configuration; these compounds of the invention are smilagenin and epismilagenin or derivatives thereof.

The invention also provides corresponding methods for the treatment of human and non-human animals, and compositions containing the active agents for use in the said treatment methods. Moreover, certain of the active agents, as well as certain intermediates used in methods for the preparation of the active agents, are new, and they themselves constitute further aspects of the present invention, as do the methods for the preparation of the active agents. These aspects are discussed in more detail below

The active agents of the invention may, if desired, be co-administered with one or more additional active agent, for example cholinesterase inhibitors and L-dopa.

Detailed Description of the Invention

5

Active Agents

In the above definition of formula II:

10 Optional amino, mono-alkyl-amino and di-alkyl-amino substituents of alkyl groups, where present, are preferably a mono-substituent at the α position of the alkyl group.

Optional -COOH substituents of alkyl groups, where present, may be at the terminal or any other position of the alkyl group.

15

"Alkyl" means an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups have 1 to about 12 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. "Lower alkyl" means about 1 to
20 about 4 carbon atoms in the chain which may be straight or branched. Exemplary alkyl groups include methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *t*-butyl, *s*-butyl, *n*-pentyl, 3-pentyl.

"Aryl" means any group comprising an aromatic ring or system of fused rings, and preferably contains up to 12 carbon atoms. An exemplary aryl group is the phenyl group. An aryl group
25 may optionally be mono- or poly-substituted, for example by substituents independently selected from halo (e.g. chloro or bromo), alkyl, cycloalkyl, hydroxy, alkoxy, amino, nitro, acylamino, carboxy and alkoxycarbonyl.

"Carboxylic acid residue" means the group -COOH.

30

"Pharmaceutically acceptable salts" means the relatively non-toxic, inorganic and organic acid addition salts, and base addition salts, of compounds of the present invention. These salts can be prepared *in situ* during the final isolation and purification of the compounds. In particular, acid addition salts can be prepared by separately reacting the purified compound in
35 its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. See, for example S. M. Berge, et al., Pharmaceutical Salts, J. Pharm. Sci., 66: p.1-19 (1977) which is incorporated herein by reference. Base addition salts can also be prepared by

separately reacting the purified compound in its acid form with a suitable organic or inorganic base and isolating the salt thus formed. Base addition salts include pharmaceutically acceptable metal and amine salts. Examples of suitable acid addition salts are those formed with acids selected from hydrochloric, sulphuric, phosphoric and nitric acids. Examples of
 5 suitable base addition salts are those formed with bases selected from sodium hydroxide, potassium hydroxide and ammonium hydroxide.

"Pharmaceutically acceptable" means that the material is, within the scope of sound medical and veterinary judgement, suitable for use in contact with the cells of humans and lower
 10 animals without undue toxicity, irritation, allergic response and the like, and is commensurate with a reasonable benefit/risk ratio.

In the above formula II, -OR may, for example, be selected from the following (unless excluded by proviso): hydroxy, cathylate (ethoxycarbonyloxy), acetate, succinate,
 15 propionate, butyrate, valerate, isovalerate, caproate, isocaproate, diethylacetate, octanoate, decanoate, laurate, myristate, palmitate, stearate, benzoate, phenylacetate, phenylpropionate, cinnamate, p-nitrobenzoyloxy, 3,5-dinitrobenzoyloxy, p-chlorobenzoyloxy, 2,4-dichlorobenzoyloxy, p-bromobenzoyloxy, m-bromobenzoyloxy, p-methoxybenzoyloxy, phthalyl, glycinate, alaninate, valinate, phenylalaninate, isoleucinate, methioninate,
 20 argininate, aspartate, cysteinate, glutaminate, histidinate, lysinate, proline, serinate, threoninate, tryptophanate, tyrosinate, fumarate and maleate.

In the above formula II, the group R may, for example, be selected from lower alkyl and lower alkoxy, optionally substituted with a terminal carboxylic acid (-COOH) residue.

25 Of the compounds of general formula II and their pharmaceutically acceptable salts, particularly preferred are the following compounds (unless excluded by proviso):

sarsasapogenin

sarsasapogenin cathylate

30 sarsasapogenin acetate

sarsasapogenin succinate and pharmaceutically acceptable salts thereof

episarsasapogenin

episarsasapogenin cathylate

episarsasapogenin acetate

35 episarsasapogenin succinate and pharmaceutically acceptable salts thereof

smilagenin

smilagenin cathylate

smilagenin acetate

smilagenin succinate and pharmaceutically acceptable salts thereof

epismilagenin

epismilagenin cathylate

5 epismilagenin acetate

epismilagenin succinate and pharmaceutically acceptable salts thereof

sarsasapogenin glycinate and pharmaceutically acceptable salts thereof

episarsasapogenin glycinate and pharmaceutically acceptable salts thereof

smilagenin glycinate and pharmaceutically acceptable salts thereof

10 epismilagenin glycinate and pharmaceutically acceptable salts thereof

sarsasapogenin alaninate and pharmaceutically acceptable salts thereof

episarsasapogenin alaninate and pharmaceutically acceptable salts thereof

smilagenin alaninate and pharmaceutically acceptable salts thereof

epismilagenin alaninate and pharmaceutically acceptable salts thereof

15 sarsasapogenin valinate and pharmaceutically acceptable salts thereof

episarsasapogenin valinate and pharmaceutically acceptable salts thereof

smilagenin valinate and pharmaceutically acceptable salts thereof

epismilagenin valinate and pharmaceutically acceptable salts thereof

sarsasapogenin phenylalaninate and pharmaceutically acceptable salts thereof

20 episarsasapogenin phenylalaninate and pharmaceutically acceptable salts thereof

smilagenin phenylalaninate and pharmaceutically acceptable salts thereof

epismilagenin phenylalaninate and pharmaceutically acceptable salts thereof

sarsasapogenin isoleucinate and pharmaceutically acceptable salts thereof

episarsasapogenin isoleucinate and pharmaceutically acceptable salts thereof

25 smilagenin isoleucinate and pharmaceutically acceptable salts thereof

epismilagenin isoleucinate and pharmaceutically acceptable salts thereof

sarsasapogenin methioninate and pharmaceutically acceptable salts thereof

episarsasapogenin methioninate and pharmaceutically acceptable salts thereof

smilagenin methioninate and pharmaceutically acceptable salts thereof

30 epismilagenin methioninate and pharmaceutically acceptable salts thereof.

A particularly preferred active agent is episarsasapogenin and its cathylate, acetate, succinate, glycinate, alaninate, valinate, phenylalaninate, isoleucinate and methioninate esters, and pharmaceutically acceptable salts thereof.

35

The active agents may be formulated for delivery as pharmaceutically acceptable prodrugs, which term shall be understood in the same way as defined in WO-A-01/23406, referred to

above. Examples of such prodrugs include forms of the 3-OH compounds in which the moiety at the 3-position is a sulphonyl (-OSO₃H), phosphonyl -OP(O)(OH)₂, optionally substituted arylcarbonyloxy or optionally substituted alkyl-carbamoyloxy group.

5 *Compositions and Uses*

According to a further aspect of the present invention, there is provided a method for treating or preventing non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, or receptor loss in the absence of cognitive, neural or neuromuscular impairment, in a human or non-human animal in need thereof, which comprises administering to the said human or non-human animal an effective dosage of a compound of general formula II as defined above or a pharmaceutically acceptable salt thereof.

According to a further aspect of the present invention, there is provided a method for treating or preventing cognitive dysfunction in a human or non-human animal in need thereof, which comprises administering to the said human or non-human animal an effective dosage of a compound of general formula II as defined above or a pharmaceutically acceptable salt thereof; provided that: R is not hydrogen or unsubstituted acetyl unless simultaneously the stereochemistry of C3 is α and of C25 is S; R is not unsubstituted ethoxycarbonyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is R; and R is not succinyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is S or the stereochemistry of C3 is R(α) and of C25 is R.

The active agent may be administered in the form of a composition comprising the active agent and any suitable additional component. The composition may, for example, be a pharmaceutical composition (medicament), a foodstuff, food supplement or beverage. Such a composition may contain a mixture of the specified compounds, and/or of their pharmaceutically acceptable salts.

According to a further aspect of the present invention, there is provided a composition having activity against non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, or receptor loss in the absence of cognitive, neural or neuromuscular impairment, in a human or non-human animal, which comprises an effective amount of a compound of general formula II as defined above or a pharmaceutically acceptable salt thereof.

According to a further aspect of the present invention, there is provided a composition having activity against cognitive dysfunction in a human or non-human animal, which comprises administering to the said human or non-human animal an effective dosage of a compound of general formula II as defined above or a pharmaceutically acceptable salt thereof; provided that: R is not hydrogen or unsubstituted acetyl unless simultaneously the stereochemistry of C3 is α and of C25 is S; R is not unsubstituted ethoxycarbonyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is R; and R is not succinyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is S or the stereochemistry of C3 is R(α) and of C25 is R.

The term "pharmaceutical composition" in the context of this invention means a composition comprising an active agent and comprising additionally pharmaceutically acceptable carriers, diluents, adjuvants, excipients, or vehicles, such as preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms.

The terms "foodstuff", "food supplement" and "beverage" used herein have the normal meanings for those terms, and are not restricted to pharmaceutical preparations.

The dosage of the active agent will vary widely, depending on the severity of the symptoms to be treated or prevented. The selection of appropriate dosages is within the ability of one of ordinary skill in this art, without undue burden. The dosage of the active agent may, for example, be greater than about 0.3 mg/kg body weight, preferably administered once per day. More typically, the dosage will be between about 1 and about 25 mg/kg, e.g. between about 1 and about 10 mg/kg, preferably administered once per day. The compositions may suitably be formulated as unit dosage forms, adapted to administer a unit dosage of between about 1 and about 10 mg/kg to the patient, the number and frequency of administrations in a particular time period to be as instructed. For human use, the dosage may conveniently be between about 70 and about 700 mg per day.

"Pharmaceutically acceptable dosage forms" means dosage forms of the compounds or compositions of the invention, and includes, for example, tablets, dragees, powders, elixirs, syrups, liquid preparations, including suspensions, sprays, inhalants tablets, lozenges, emulsions, solutions, granules, capsules and suppositories, as well as liquid preparations for injections, including liposome preparations. Techniques and formulations generally may be

found in Remington, Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, latest edition.

In general, reference herein to the presence of one of a specified group of compounds includes
5 within its scope the presence of a mixture of two or more of such compounds.

According to a further aspect of this invention, there is provided a method for the treatment of cognitive dysfunction in a patient suffering from one of: Alzheimer's disease, SDAT, AAMI, Lewi body dementia or autism, which method comprises administering to the patient a
10 pharmacologically effective amount of a compound of formula II or of a pharmaceutically acceptable salt thereof; provided that: R is not hydrogen or unsubstituted acetyl unless simultaneously the stereochemistry of C3 is α and of C25 is S; R is not unsubstituted ethoxycarbonyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is R; and
15 R is not succinyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is S or the stereochemistry of C3 is R(α) and of C25 is R.

According to a further aspect of this invention, there is provided a method for enhancing cognitive function in a human or non-human animal, which method comprises administering to the patient an effective amount of a compound of formula II or of a pharmaceutically
20 acceptable salt thereof; provided that: R is not hydrogen or unsubstituted acetyl unless simultaneously the stereochemistry of C3 is α and of C25 is S; R is not unsubstituted ethoxycarbonyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is R; and
R is not succinyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is S or the stereochemistry of C3 is R(α) and of C25 is R. The treatment may be a non-therapeutic
25 method practiced on a normal subject, for enhancing the subject's cognitive function.

According to a further aspect of this invention, there is provided a method for the treatment of (i) non-cognitive neurodegeneration, (ii) non-cognitive neuromuscular degeneration, or (iii) receptor loss in the absence of cognitive, neural or neuromuscular impairment, in a human or
30 non-human animal in a patient suffering from one of: Parkinson's disease, muscular dystrophy including facioscapulohumeral muscular dystrophy (FSH), Duchenne muscular dystrophy, Becker muscular dystrophy and Bruce's muscular dystrophy, Fuchs' dystrophy, myotonic dystrophy, corneal dystrophy, reflex sympathetic dystrophy syndrome (RSDSA), neurovascular dystrophy, myasthenia gravis, Lambert Eaton disease, Huntington's disease,
35 amyotrophic lateral sclerosis (ALS), multiple sclerosis, postural hypotension, chronic fatigue syndrome, asthma, susceptibility to heart failure, and macular degeneration, which method

comprises administering to the patient a pharmacologically effective amount of a compound of formula II or of a pharmaceutically acceptable salt thereof.

5 The methods of enhancing cognitive or neurological function and the methods of treating certain conditions, as defined above, may be accomplished by administering the compound or composition or medicament, as the case may be, in the form of a pharmaceutical composition, foodstuff, food supplement or beverage.

10 The invention also provides the use of one or more compound of formula II or of a pharmaceutically acceptable salt thereof as an ingredient in a pharmaceutical composition, food product, food supplement or beverage in a method for the treatment of Parkinson's disease, muscular dystrophy including facioscapulohumeral muscular dystrophy (FSH), Duchenne muscular dystrophy, Becker muscular dystrophy and Bruce's muscular dystrophy, Fuchs' dystrophy, myotonic dystrophy, corneal dystrophy, reflex sympathetic dystrophy
15 syndrome (RSDSA), neurovascular dystrophy, myasthenia gravis, Lambert Eaton disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, postural hypotension, chronic fatigue syndrome, asthma, susceptibility to heart failure, and macular degeneration.

20 The invention also provides the use of one or more compound of formula II or of a pharmaceutically acceptable salt thereof, provided that: R is not hydrogen or unsubstituted acetyl unless simultaneously the stereochemistry of C3 is α and of C25 is S; R is not unsubstituted ethoxycarbonyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is R; and R is not succinyl when simultaneously the stereochemistry of C3 is S(β) and
25 of C25 is S or the stereochemistry of C3 is R(α) and of C25 is R; as an ingredient in a pharmaceutical composition, food product, food supplement or beverage in a method for the treatment of Alzheimer's disease, SDAT, AAMI, MCI and autism.

Preparation of Compounds for Use in the Invention

30 Smilagenin, epismilagenin, sarsasapogenin and episarsasapogenin are commercially available materials. Suppliers include, for example, Sigma Aldrich, Research Plus Inc. and Steraloids Inc. Preparative methods for these materials are also to be found in the literature (e.g. a preparation of episarsasapogenin is given in JACS p.5225 (1959)). Episarsasapogenin can be
35 prepared by reduction of sarsasapogenone using a metal hydride reducing agent. Sarsasapogenone can be prepared using the method of Lajis et al, Steroids, 1993, 58, 387-389.

Also, as starting materials, unsubstituted sapogenins may occur naturally in a range of plant species, notably plants of the genus *Smilax*, *Asparagus*, *Anemarrhena*, *Yucca* or *Agave*. Where *smilagenin* or *sarsasapogenin* is used in accordance with this invention, it may be in the form of a plant extract, or dry powdered plant material, derived from a plant of the genus *Smilax*, *Asparagus*, *Anemarrhena*, *Yucca* or *Agave*.

The compounds of formula II, other than those with $R = H$, can be prepared using conventional techniques from compounds in which $R = H$. The preferred reaction is a nucleophilic substitution reaction, in which a compound of formula II in which $R = H$ is reacted with a compound of formula



in which selected from hydrogen; alkylcarbonyl; or alkoxycarbonyl; wherein any alkyl group is optionally substituted with aryl, amino, mono-alkyl-amino, di-alkyl-amino, a carboxylic acid residue ($-COOH$), or any combination thereof; and L is a leaving group, under conditions suitable for nucleophilic substitution.

The compound L-R may, for example, be a carboxylic acid or, if appropriate, an anhydride, or an acyl halide (e.g. an acyl chloride). For example, where R is a cathylate (ethoxycarbonyl) moiety, the compound L-R may suitably be ethyl chloroformate.

The reaction is suitably performed in a base such as pyridine, optionally in the presence of an acid such as hydrochloric acid.

The reaction details for nucleophilic substitution reactions are well known. See, for example, RC Larock, in *Comprehensive Organic Transformations*, VCH publishers, 1989.

In the reactions described herein it may be necessary to protect reactive functional groups, for example hydroxy, carboxy or amino groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice. For examples, see TW Green and PGM Wuts, in "Protective Groups in Organic Chemistry", John Wiley & Sons, 1991; JFW McOmie in "Protective Groups in Organic Chemistry", Plenum Press, 1973. For protecting amino substituents in compounds of formula L-R wherein R is amino-substituted, it is preferred to use an alkoxycarbonyl protecting group, whereby the amino function is present as an

alkoxycarbonylamino group (preferably t.butoxycarbonylamino) during the synthetic steps, until deprotection in acid conditions in a dry solvent.

5 The compound thus prepared may be recovered from the reaction mixture by conventional means. For example, the compound may be recovered by distilling off the solvent from the reaction mixture or, if necessary after distilling off the solvent from the reaction mixture, pouring the residue into water, followed by extraction with a water-miscible solvent and distilling off the solvent from the extract. Additionally, the product can, if desired, be further purified by various well known techniques, such as recrystallisation, reprecipitation, or the
10 various chromatography techniques, notably column chromatography or preparative thin layer chromatography.

Novel Compounds

15 Certain of the compounds of general formula II, and the protected intermediates in the methods for their preparation, and their salts, are new *per se*, and these novel compounds constitute a further aspect of the present invention.

20 According to a further aspect of the present invention, there are provided compounds of the general formula II, wherein the group R is selected from alkylcarbonyl; or alkoxycarbonyl; wherein any alkyl group is optionally substituted with aryl, amino, alkoxycarbonylamino, mono-alkyl-amino, di-alkyl-amino, N-alkyl,N-alkoxycarbonyl-amino, or a carboxylic acid residue (-COOH), or any combination thereof; provided that:

25 R is not unsubstituted acetyl unless simultaneously the stereochemistry of C3 is α and of C25 is S;

R is not unsubstituted ethoxycarbonyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is R;

30 R is not succinyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is S or the stereochemistry of C3 is R(α) or S(β) and of C25 is R; and

35 R is not propionyl, butyryl, valeryl, isovaleryl, caproyl, isocaproyl, diethylacetyl, octanoyl, decanoyl, lauryl, myristyl, palmityl, stearyl, benzoyl, phenylacetyl, phenylpropionate, cinnamate, p-nitrobenzoate, 3,5-dinitrobenzoate, p-chlorobenzoate, 2,4-dichlorobenzoyl, p-bromobenzoyl, m-bromobenzoyl, p-methoxybenzoyl, benzenesulphonyl, p-toluenesulphonyl,

cyclopentylpropionyl, furoyl, or phthalyl when the stereochemistry of C25 is R and the stereochemistry of C3 is S(β);

(including, subject to the provisos, all stereoisomers and racemic mixtures thereof), and salts thereof.

There may be mentioned particularly as novel compounds the compounds of formula II in which R is any of the above stated groups except acetyl.

- 10 Novel salts of the compounds of general formula II, including novel salts of compounds of general formula II which are not themselves pharmaceutically acceptable, may find use as intermediates in methods for the preparation of the compounds of general formula II and their pharmaceutically acceptable salts.

15 *Discussion of the Basis for the Activity*

Without wishing to be bound by theory, it is believed that the compounds defined above exhibit the ability to regulate receptors. For example, some of these compounds have been found to prevent or reverse the loss of muscarinic receptors or dopamine receptors in the brain. It is believed that the compounds function by rectifying a deficiency in receptor number or function or turnover in the animal being treated.

One hypothesis is that the compounds are increasing the synthesis or release of, or are decreasing the rate of degradation of, neurotropic factors such as brain derived growth factor and/or nerve growth factor. These effects on growth factors might be due to an effect of the compound on a cytosolic or nuclear receptor, or the binding of a compound to a promoter region with a consequent effect directly on the rate of production of mRNA for the growth factor, or as a consequence of increasing the production of another material factor.

- 30 The increased expression and/or abnormal processing of the amyloid precursor protein (APP) is associated with the formation of amyloid plaques and cerebrovascular amyloid deposits which are the major morphological hallmarks of Alzheimer's disease. Of particular interest are the processes regulating the proteolytic cleavage of APP into amyloidogenic and nonamyloidogenic fragments. The cleavage of APP by the enzyme α -secretase within the β -amyloid sequence of the protein results in the formation of a non amyloidogenic C-Terminal fragment, and the soluble APP α fragment; this latter fragment has been shown to have neurotropic and neuroprotective activity as well as to enhance memory in mice when injected

intra-cerebro-ventrically (ICV). In contrast, processing of APP by β -secretase exposes the N-terminus of β -amyloid which is released by γ -secretase cleavage at the variable C-terminus. The resulting β -amyloid peptides, which contain 39-43 amino acids, have been shown to be neurotoxic and to accumulate in plaques which interfere with inter-neurone connections.

5

A number of studies have shown that stimulation of muscarinic receptors results in an increase in α -secretase activity. As a consequence processing of APP to APPs α with its neuroprotective effects is increased. In parallel, processing of APP by β - and γ -secretase is decreased and there is a consequential reduction of β -amyloid. Other transmitters such as nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) as well as bradykinin and vasopressin may have similar effects in increasing the proportion of APP processed to APPs α . There may be a number of factors involved in the effects of NGF which may include binding of the factor to the tyrosine kinase receptor (TrkA) and the stimulation of phospholipase C γ with subsequent phosphorylation and activation of protein kinase C (PKC) and increase in relative activity of α -secretase.

15

Compounds according to this invention which reverse the loss of, and/or increase, muscarinic receptor numbers will have particular utility. Indeed the benefits may be seen in three parts as follows.

20

1. An increase in muscarinic receptor numbers leading to increased synaptic transmission; the reversal of the loss of, and/or increase in, the number of nicotinic receptors, which lie upstream of the synaptic cleft, will lead to an increase in, or a reversal of loss of, acetylcholine release into the synaptic cleft, thereby increasing muscarinic receptor activation and thus amplifying the overall effect.

25

2. Secondary to the increased receptor numbers with a consequential increase in α -secretase activity, leading to:

30

2.1 A reduced production of β -amyloid and a consequent reduction of plaque formation and neuronal loss;

2.2 An increase in APPs α and a consequent improvement in cerebral function as witnessed by an improvement in short and long term memory.

Brief Description of the Drawings

5

In order to illustrate the invention further by way of non-limiting example, reference will now be made to the accompanying drawings and to the Examples which follow.

In the drawings:

10

Figure 1 illustrates a hypothetical mode of action for the compounds employed in the methods of this invention;

15

Figure 2 shows the effects of sarsasapogenin, episarsasapogenin cathylate and smilagenin on the learning ability and memory of aged rats;

Figure 3 shows the effects of sarsasapogenin, episarsasapogenin cathylate and smilagenin on muscarinic receptor number;

20

Figure 4 shows the effects of sarsasapogenin, episarsasapogenin cathylate and smilagenin on glutamate induced neurodegeneration in rat primary cortical neurons; and

Figure 5 shows the effect of epismilagenin acetate on m3 and β 2 adrenoceptor density at day 5 in a CHO- β 2/m3 co-transfected cell line.

25

Detailed Description of the Drawings and Examples

30

Referring to Figure 1 of the drawings, a diagrammatic representation of the function of the compounds of the invention is shown. It is believed that the compounds act primarily on cell nuclei; the invention is not, however, limited to any particular mode of action. The observed increase in receptor number consequential upon administration of an active agent is interpreted as leading to increased expression of muscarinic (and/or nicotinic and/or dopamine) receptor protein. The possible link between the secretases and β -amyloid protein formation (discussed above) is indicated in the drawing.

35

Figures 2 to 5 will be described in detail below, in connection with the discussion of the examples.

Epismilagenin cathylate, epismilagenin acetate, sarsasapogenin cathylate, episarsasapogenin cathylate, episarsasapogenin succinate, episarsasapogenin ethylsuccinate (comparison), sarsasapogenin, episarsasapogenin, smilagenin and epismilagenin have been tested for activity in a number of *in vitro* and *in vivo* assays. The assays/experiments that were considered of key importance in determining possible activity in the modulation of receptor numbers were as follows:

Assay 1: Cell based assay

Chinese hamster ovary (CHO) cells transfected with a vector coding for a muscarinic receptor and/or beta adrenoreceptor. The cell line used for the majority of the experiments was a cell line expressing a muscarinic receptor.

Assay 2: Alzheimer's disease model

An *in vivo* model of Alzheimer's disease in which amyloid beta and ibotenic acid are injected into the brain of the rat.

Assay 3: Learning and memory test

A Y-maze used to test learning and memory in rats exposed to the test compounds. The rats were subsequently sacrificed and the density of muscarinic receptors in the brain assayed by dual-site competitive binding assay, to correlate performance in the Y-maze, receptor density and activity of the active agents.

Assay 4: Neuroprotection of cultured neurons

An *in vitro* test of the ability of the test compounds to protect neurons against damage in an environment hostile to neurons.

Methods and Results

The methods and the results of these experiments are now described in the following Examples, which also give examples of methods of synthesis.

EXAMPLE 1**Cell based assay**

5 The effects of epismilagenin cathylate, sarsasapogenin cathylate, episarsasapogenin cathylate, episarsasapogenin succinate, epismilagenin acetate and sarsasapogenin on the expression of m receptors in CHO cells transfected with vector for the m receptor were investigated. Receptor numbers were assayed using [³H]NMS binding and subtracting non-specific binding.

10 Compounds were dissolved in dimethyl sulphoxide (DMSO) and DMSO was used as a control.

Methods:

15 Chinese hamster ovary (CHO) cells expressing high levels of muscarinic receptor (~2.2 pmol mg protein⁻¹) were plated on a 24 well plate, 1 day before the start of the experiment. The culture medium was replaced with medium containing vehicle (DMSO) or the compounds. The cells were incubated for 2/3 days, then after a medium change, cells were incubated for a further 2/3 days. The cells were incubated with a saturating concentration of labelled N-

20 methyl-scopolamine, ([³H]NMS). Cells were washed with ice cold phosphate-buffered saline (PBS) (3x) and bound [³H]NMS determined by solubilising receptors with RIPA buffer followed by liquid scintillation counting.

The results shown in Figure 5 used a CHO cell line co-transfected to express both β 2

25 adrenoceptors and m3 muscarinic receptors. To measure the β 2 and m3 receptor density, both [³H]NMS and [³H]CGP were used.

Results:

30 These are illustrated in Table 1 below and in Figure 5 of the drawings. Over the culturing period, treatment with epismilagenin cathylate, sarsasapogenin cathylate, episarsasapogenin cathylate, episarsasapogenin succinate and sarsasapogenin each prevents the decrease in muscarinic receptor number. Co-incubation of the co-transfected cell line with epismilagenin acetate (Figure 5) did not significantly alter the density of m3 receptors, whereas the decrease

35 in β 2 adrenoceptors was significantly prevented by the epismilagenin acetate.

Table 1

Compound	Concentration [microMolar]	Activity
epismilagenin cathylate	10	++
sarsasapogenin cathylate	10	++
episarsasapogenin cathylate	10	++
episarsasapogenin succinate	10	++
Sarsasapogenin	10	++

Thus, the experiments indicate that each of epismilagenin cathylate, sarsasapogenin cathylate, episarsasapogenin cathylate, episarsasapogenin succinate, epismilagenin acetate and sarsasapogenin were able to increase the number of muscarinic receptors or adrenoceptors expressed in CHO cells cultured *in vitro*. The compounds of this invention act to normalise receptor number i.e. they tend to prevent decline in receptor number with time and also tend to restore receptor number to normal levels when given to cells in which the receptor level is depressed.

EXAMPLE 2

Alzheimer's disease model

An *in vivo* model of Alzheimer's disease was used in which amyloid beta and ibotenic acid are injected into the brain of the rat, which leads to a receptor loss in the brain and cognitive impairment. Previous studies showed that local injection of amyloid β in the nucleus vasalis of the rat brain caused cholinergic hypofunction and behavioural impairment up to two months post surgery (Giovannelli et al., 1995: Neuroscience, 66, 781-792.). In addition the co-injection of amyloid β with a small amount of ibotenic acid into the rat hippocampus synergistically produces neuronal loss with infiltration of glial cells not only adjacent but also far from the injected site (Morimoto et al., 1998: Neuroscience, 84, 479-487).

Methods:

Our studies used the method of Morimoto (Morimoto et al., 1998: Neuroscience, 84, 479-487) with some modifications (unilateral instead of bilateral injection). Three months old, Sprague Dawley rats, were randomly divided into different groups. Injection of amyloid β_{1-40} and

ibotenic acid (both from Sigma) was accomplished by means of a stereotaxic instrument (Stoelting Co.) and the coordinates were AP= -0.5mm (right to medial line), L= -2.8mm (backward from bregma), H= -7.0mm (ventral to dura). The dose for each rat was amyloid β_1 -40 (4 μ g) and ibotenic acid (1 μ g) in 1 μ l of saline. The injection was completed in 20 min, and the needle was withdrawn 10 min later. Then the skin was sutured.

The 8 groups were:

- Operated control injected with normal saline (control)
- Model (control injected with amyloid β + ibotenic acid)
- Model + Episarsasapogenin cathylate (18 mg/kg/day)*
- Model + Sarsasapogenin cathylate (18 mg/kg/day)*
- Model + Episarsasapogenin ethylsuccinate (18 mg/kg/day) (comparison)
- Model + Episarsasapogenin (18 mg/kg/day)*
- Model + Epismilagenin (18 mg/kg/day)*
- Model + Diosgenin (i.e. negative control, 18 mg/kg/day)

* Compounds in accordance with the present invention

Drug administration

Episarsasapogenin cathylate, sarsasapogenin cathylate, episarsasapogenin ethylsuccinate (comparison compound), episarsasapogenin, epismilagenin and diosgenin (all at a dosage of 18 mg/kg/day) were administered to animals as stable suspensions in CMC-Na (0.5%) once daily through a gastric tube. The control and the Alzheimer's model group were given the same volume of CMC-Na (0.5%) once daily. The drugs and vehicles were given for a period of two months, starting 20 days before operation.

Measurement of muscarinic-receptor density

The brain samples were homogenised, centrifuged, and the pellet of centrifugation at 27000 \times g was re-homogenised and used for measurement. The concentration of ^3H -QNB was chosen at the saturation range. After incubation and separation, the bound portion was measured by liquid scintillation counter.

Step-Through Test

The effect of test compounds on memory was assessed using the step-through test. A 60 × 15 × 15 cm box, divided into 2 equally sized rooms, one dark room with copper rod base, which was electrically charged (40 V ac) when in use, while the other was a light room but not electrically charged. Between the two rooms there is an opening (hole) for the rat to go through. The experiment is carried out for each rat on two consecutive days. The first day is for training; when the rat is adapted in the box for the first 3 min, then put in the light room, with its back toward the hole, and the copper rods of the dark room are charged for 5 min. The second day is for testing, when the number of crosses in 5 min are recorded. Improvements in memory are signalled by a reduction in the number of crosses.

Results

The muscarinic receptor density in Alzheimer's model brains was significantly lower than control. Episarsasapogenin cathylate, sarsasapogenin cathylate, episarsasapogenin and epismilagenin produced a significant elevation in brain muscarinic receptor density, whereas diosgenin and episarsasapogenin ethylsuccinate did not significantly change the muscarinic receptor density. Thus the experiments indicate that the compounds of this invention act to normalise receptor number, i.e. they tend to restore receptor number to normal levels when given to animals in which the receptor level is depressed.

The number of wrong responses (error number) in 5 min was significantly higher in the Alzheimer's model group than the control group, indicating an impairment of memory (see Table 2 below). Epismilagenin, episarsasapogenin cathylate, episarsasapogenin and sarsasapogenin cathylate each significantly decreased the number of wrong responses, whereas diosgenin and episarsasapogenin ethylsuccinate were both ineffective in decreasing the number of wrong responses.

Table 2

Group	Muscarinic receptor Density	Step through test
	(fmol/mg/protein)	Error No
Control (n=10)	859±101	0.60±0.70
Model (n=10)	713±48	4.00±2.40

Model + Episarsasapogenin cathylate (n= 10)	877±89 *	1.36±0.92*
Model + Sarsasapogenin cathylate (n=11)	916±158 *	1.36±1.03 *
Model + Episarsasapogenin ethylsuccinate (n=11)	774±79	3.73±1.35
Episarsasapogenin (n=10)	869±104*	1.50±1.18*
Epismilagenin (n=11)	877±90*	1.73±0.91*
Model + Diosgenin (n=8)	770±68	3.75±1.49

Statistical analysis using unpaired Student t test. * denotes $p < 0.05$

EXAMPLE 3

5

Learning and memory test

10 Aged Sprague-Dawley rats aged were divided randomly into 4 groups, one control and groups treated for three months with either sarsasapogenin, episarsasapogenin cathylate or smilagenin ($18 \text{ mg kg}^{-1} \text{ day}^{-1}$, $n = 10$). A control group ($n=14$) of untreated young rats was also included in the study. The daily dose of drug was mixed in a minimum amount of food and was administered every morning separately to each rat.

15 A Y-maze apparatus was used for the learning and memory test. On the floor of each arm of the Y-maze is an array of copper rods to which electric current is applied whenever needed, with adjustable voltage. Each arm is 45 cm long and has a 15 W lamp at the end, which is turned on when needed. After 3 months drug administration, each rat was trained for 7 consecutive days, as follows. For each training session, the rat was put into one arm of the Y-maze, after two minutes rest, an electrical current was applied to the copper rods and the lamp of the clockwise arm was illuminated to indicate the non-stimulation area. If the rat went into that arm, one correct response was recorded, otherwise, one wrong response was recorded. This stimulation-response test was repeated 20 times each day, with a pause of 5 sec between each two consecutive tests. The number of correct responses following the twenty tests on the seventh day was used to express learning ability, (the higher the number the better the learning ability). The rats were then left resting for 30 days and the procedure was repeated 25 once more. The number of correct responses of the 20 tests after the 30 day rest period was used to represent the memory ability

Measurement of muscarinic receptor density in the brain

5 Tissue preparation: Brains were removed quickly after decapitation, frozen in dry ice, and transferred to a freezer. The brains were homogenised and the pellet was finally suspended in buffer.

10 Dual-site competitive ligand binding assay: ^3H -QNB (quinuclidinyl benzilate) was used as the radio-ligand which was non-selective to M receptor subtypes *in vitro*. Pirenzepine was used as the selective non-radioactive competing agent. Protein concentration was determined by the micro-Lowry method.

15 The results are shown in Figures 2 and 3 of the drawings. The Y-maze experiments revealed that both the learning ability and memory are impaired in aged rats. Sarsasapogenin, episarsasapogenin cathylate and smilagenin restored the learning and memory ability following administration in aged rats. Muscarinic receptor density was markedly reduced in aged rats. Sarsasapogenin, episarsasapogenin cathylate and smilagenin significantly restored the muscarinic receptor number.

20 Conclusions

Sarsasapogenin, episarsasapogenin cathylate and smilagenin significantly restores the muscarinic receptor density in the aged rat brain toward that of young rats. The restoration of muscarinic receptor density in aged rat brain induced by sarsasapogenin, episarsasapogenin cathylate and smilagenin is associated with an increase in learning ability and memory.

EXAMPLE 4

30 Neuroprotective effect of sarsasapogenin, episarsasapogenin cathylate and smilagenin

The objective of this study was to examine the effects of sarsasapogenin, episarsasapogenin cathylate and smilagenin on the survival of rat primary cortical cultures treated with glutamate, which is known to induce neurodegeneration.

Primary cultures of cortical neurons

5 Rat cortical neurons were cultured for 10 days; at day 10 the medium was changed to a serum-free defined medium. On day 12, 24 hours before glutamate exposure, cultures were washed and medium was replaced with fresh medium containing positive control (β -oestradiol), test compounds (sarsasapogenin, episarsasapogenin cathylate or smilagenin) or vehicle control (DMSO, 0.25%).

10

On day 13, cultures were exposed to glutamate.

After the incubation period, the cultures were washed with and placed in fresh medium, supplemented with relevant compounds or vehicle to evaluate their protective effects, 24 h
15 after glutamate exposure.

Neuronal cell survival was evaluated by measuring lactate dehydrogenase (LDH) activity released in the media 24 h after test compound treatment or glutamate + test compound exposure, using the CytoTox 96 non-radioactive kit and quantitated by measuring wavelength
20 absorbance at 450 nm.

Results

Following treatment of rat primary cortical cultures with glutamate, there was a significant
25 degeneration of cortical neurons, 24 h post-treatment, demonstrated by an increase in lactate dehydrogenase release into the culture medium.

In primary cortical cultures pre-treated with sarsasapogenin, episarsasapogenin cathylate or smilagenin for 24 h, there was also a significant reduction in the glutamate-induced
30 neurodegeneration (Figure 4)

Conclusions

Sarsasapogenin, episarsasapogenin cathylate or smilagenin all displayed significant neuroprotective effects against glutamate-induced neurodegeneration in rat primary cortical neurons *in vitro*.

EXAMPLE 5

Synthesis of Sarsasapogenin cathylate (3-Ethoxycarbonyl 5 β ,20 α ,22 α ,25S-spirostan-3- β -ol)

Ethyl chloroformate (1.40 g, 12.9 mmol) was added dropwise to a stirred solution of sarsasapogenin (2.08 g, 5.0 mmol) in dry dichloromethane (20 ml) and dry pyridine (1.02 g, 12.9 mmol). The mixture was stirred at room temperature for 18h and then partitioned between water (30 ml) and dichloromethane. The aqueous layer was extracted twice with dichloromethane, the combined organic layers washed with water and then dried over MgSO₄. The solvent was evaporated in vacuo to give an off-white solid (2.6 g). This material was chromatographed on silica using elution with ethyl acetate-hexane (1:9) followed by recrystallisation from acetone (2x) to afford sarsasapogenin cathylate as white crystals (0.72 g, 29%): mp 133-135°C; m/z 488 (M⁺ for C₃₀H₄₈O₅); ¹H NMR (270 MHz, CDCl₃) δ 0.76 (3H, s, 18-CH₃), 0.98 (3H, s, 19-CH₃), 0.99 (3H, d, J = 6.4 Hz, 21-CH₃), 1.08 (3H, d, J = 7.0 Hz, 27-CH₃), 1.09-2.10 (27H, complex m, aliphatic H) overlapping on 1.31 (3H, t, J = 7 Hz, CO₂-C-CH₃), 3.30 (1H, brd, 26-OCHH), 3.95 (1H, brdd, J = 2.7, 10.9 Hz, 26-OCHH), 4.18 (2H, q, J = 7 Hz, CO₂CH₂), 4.40 (1H, brdd, J = 8.8, 7.2 Hz, 16-OCH), 4.95 (1H, br peak, H-3) ppm; ¹³C NMR (67 MHz, CDCl₃) δ 14.3 (C-21, C-C-O₂C), 16.1, 16.5, 20.9, 23.7, 25.0, 25.8, 26.0, 26.3, 26.4, 27.1, 30.5, 30.6, 31.7, 35.0, 35.3, 37.1, 40.0, 40.3, 40.7, 42.1, 56.4 (C-14), 62.1 (C-17), 63.5 (C-O₂C), 65.1 (C-26), 74.8 (C-3), 81.0 (C-16), 109.7 (C-22), 154.8 (carbonyl) ppm; R_f 0.7 (silica, ethyl acetate-hexane, 1:4).

EXAMPLE 6

Synthesis of Episarsasapogenin cathylate (3-Ethoxycarbonyl 5 β ,20 α ,22 α ,25S-spirostan-3 α -ol)

A solution of lithium tri-tert-butoxyaluminumhydride in tetrahydrofuran (1M, 150 ml, 0.15 mol) was carefully added (over 20 min) to a stirred solution of sarsasapogenone (produced by the method of Lajis et al, Steroids, 1993, 58, 387-389) (41.4 g, 0.10 mol) in dry tetrahydrofuran (400 ml) at $20 \pm 5^\circ\text{C}$ under dry nitrogen. The reaction mixture was stirred at room temperature for 2h. The resulting solution was carefully quenched with aqueous saturated sodium sulfate solution (50 ml), the inorganic salts removed by filtration through a hyflo pad, and washed with THF. The solvents were removed in vacuo and the residue (ca. 40 g) partitioned between ethyl acetate (500 ml) and 1M hydrochloric acid (200 ml). At the interface of the two solvents a white material remained undissolved that was removed by filtration, washed with water (2 x 100 ml) and dried under vacuum. The solid was slurried twice with ethyl acetate (2 x 250 ml, 5 min each), the solvents decanted off and the insoluble material dried in a vacuum oven. This yielded 23.1 g of crude episarsasapogenin that was recrystallised from acetone (1500 ml) to afford episarsasapogenin as white crystals (12.6 g, 30%); mp $214-216^\circ\text{C}$; m/z 416 (M^+ for $\text{C}_{27}\text{H}_{44}\text{O}_3$); ^1H NMR (270 MHz, CDCl_3) δ 0.75 (3H, s, 18- CH_3), 0.94 (3H, s, 19- CH_3), 0.99 (3H, d, $J = 6.6$ Hz, 21- CH_3), 1.08 (3H, d, $J = 7.3$ Hz, 27- CH_3), 1.1-2.1 (27H, complex m, aliphatic H), 3.30 (1H, brd, $J = 11.0$ Hz, 26-OCHH), 3.55-3.72 (1H, 7 line m, $J = 11.0, 5.5, 5.5$ Hz, H-3), 3.95 (1H, dd, $J = 11.0, 2.6$ Hz, 26-OCHH), 4.40 (1H, dd, $J = 8.0, 5.5$ Hz, 16-OCH) ppm; ^{13}C NMR (67 MHz, CDCl_3) δ 14.3 (C-21), 16.1 (C-27), 16.5 (C-18), 20.6 (C-11), 23.4 (C-19), 25.8 (C-24), 26.0 (C-23), 26.7 (C-6), 27.1 (C-25, C-7), 30.5 (C-2), 31.8 (C-15), 34.7 (C-10), 35.4 (C-1), 35.5 (C-8), 36.5 (C-4), 40.3 (C-12), 40.5 (C-9), 40.6 (C-13), 42.0 (C-5), 42.1 (C-20), 56.4 (C-14), 62.1 (C-17), 65.1 (C-26), 71.8 (C-3), 81.0 (C-16), 109.7 (C-22) ppm; R_f 0.35 (silica, ethyl acetate-hexane, 1 :4). A second crop was subsequently obtained (5.2 g). The ethyl acetate extracts from the above experiment were concentrated to ca. 1/5 volume to afford a further crop of episarsasapogenin (3.6 g).

Ethyl chloroformate (14.0 g, 0.13 mol) was added dropwise to a stirred solution of episarsasapogenin (10.0 g, 0.024 mol) in dry dichloromethane (200 ml) and dry pyridine (10.2 g, 0.13 mol). The pink mixture was stirred at room temperature for 18h and then partitioned between water (30 ml) and dichloromethane. The aqueous layer was extracted twice with dichloromethane, the combined organic layers washed with water and then dried over MgSO_4 .

The solvent was evaporated in vacuo to afford an off-white solid (13.4 g). Recrystallisation from acetone (ca. 300 ml) yielded episarsasapogenin cathylate as white crystals (8.9 g, 76%); mp $154-156^\circ\text{C}$; m/z 488 (M^+ for $\text{C}_{30}\text{H}_{48}\text{O}_5$); ^1H NMR (270 MHz, CDCl_3) δ 0.75 (3H, s, 18- CH_3), 0.95 (3H, s, 19- CH_3), 0.99 (3H, d, $J = 6.6$ Hz, 21- CH_3), 1.08 (3H, d, $J = 7.0$ Hz, 27- CH_3), 1.1-2.1 (27H, complex m, aliphatic H) overlapping with 1.30 (3H, t, $J = 7.1$ Hz, $\text{CO}_2\text{-CH}_3$), 3.30 (1H, brd, $J = 11.0$ Hz, 26-OCHH), 3.95 (1H, dd, $J = 11.0, 2.6$ Hz, 26-OCHH), 4.18 (2H, q, $J = 7$ Hz, CO_2CH_2), 4.41 (1H, brdd, $J = 8.0, 6.3$ Hz, 16-OCH), 4.51-4.66 (1H, 7 line m, H-3) ppm; ^{13}C NMR (67 MHz, CDCl_3) δ 14.3 (C-C- O_2C), 14.4 (C-21), 16.1, 16.5,

20.6, 23.3, 25.8, 26.0, 26.5, 26.6, 26.9, 27.1, 31.7, 32.1, 32.8, 34.7, 35.0, 35.4, 40.3, 40.5, 40.6, 41.8, 42.1, 56.4 (C-14), 62.1 (C-17), 63.6 (C-O₂C), 65.1 (C-26), 77.9 (C-3), 81.0 (C-16), 109.7 (C-22), 154.6 (carbonyl) ppm; *R_f* 0.75 (silica, ethyl acetate-hexane, 1:4).

5 EXAMPLE 7

Synthesis of Episarsasapogenin succinate (mono-3 α ,5 β ,20 α ,22 α ,25S-spirostan-3 α -succinate)

- 10 Episarsasapogenin (8.0 g, 19.2 mmol) and succinic anhydride (8.0 g; 80 mmol) were pulverized with a pestle and mortar until a homogeneous mixture of small particle size was obtained. The powdery mixture was then stirred and heated at 80°C on an oil bath while dry pyridine (0.2 ml) was added. The mixture was stirred under nitrogen as the temperature of the bath was raised to 120 \pm 5°C to obtain a 'melt', and the melt was maintained at this
- 15 temperature for 0.5 h. After cooling, the resulting solid was slurried in water (300 ml), acidified with 1M hydrochloric acid and the mixture triturated. The resulting grey tinged solid was collected by filtration, washed with water, dried and recrystallised from methanol (ca. 400 ml), with hot filtration through decolourising charcoal, to afford episarsasapogenin succinate as white crystals (7.46 g, 75%): mp 195-197°C; *m/z* 516 (*M*⁺ for C₃₁H₄₈O₆); ¹H
- 20 NMR (270 MHz, CDCl₃) δ 0.76 (3H, s, 18-CH₃), 0.95 (3H, s, 19-CH₃), 1.00 (3H, d, *J* = 6.2 Hz, 21-CH₃), 1.08 (3H, d, *J* = 7.0 Hz, 27-CH₃), 1.2-2.1 (27H, complex m, aliphatic H), 2.63 (4H, m, COCH₂CH₂CO), 3.31 (1H, brd, *J* = 11.0 Hz, 26-OCHH), 3.96 (1H, dd, *J* = 11.0, 2.6 Hz, 26-OCHH), 4.42 (1H, brdd, *J* = 8.0, 6.4 Hz, 16-OCH), 4.75 (1H, m, H-3) ppm; ¹³C NMR (67 MHz, CDCl₃) δ 14.3 (C-21), 16.1 (C-27), 16.5 (C-18), 20.6 (C-11), 23.4 (C-19), 25.8,
- 25 25.9, 26.6, 27.0, 27.1, 29.1, 29.3, 31.7 (CCO₂), 32.1 (CCO₂), 34.7, 35.1, 35.5, 40.2, 40.6, 40.7, 41.9, 42.2, 56.3 (C-14), 62.1 (C-17), 65.1 (C-26), 74.9 (C-3), 81.0 (C-16), 109.8 (C-22), 171.7 (ester carbonyl), 177.9 (carboxyl) ppm; *R_f* 0.14 (silica, ethyl acetate-hexane, 3:7).

EXAMPLE 8

30

Synthesis of Epismilagenin cathylate (3-Ethoxycarbonyl 5 β ,20 α ,22 α ,25R-spirostan-3 α -ol)

- Ethyl chloroformate (1.40g, 12.9 mmol) was added dropwise to a stirred solution of
- 35 epismilagenin (1.0 g, 2.4 mmol) in dry dichloromethane (30 ml) and dry pyridine (1.02 g,

12.9 mmol). The pink mixture was stirred at room temperature for 4h and then partitioned between water (50 ml) and dichloromethane. The aqueous layer was extracted twice with dichloromethane, the combined organic layers washed with water and then dried over MgSO₄. The solvent was evaporated in vacuo to give a pale yellow solid (1.1 g). Recrystallisation from acetone afforded epismilagenin cathylate as white crystals (0.47 g, 40%); mp 176-179°C; m/z 488 (M⁺ for C₃₀H₄₈O₅) ¹H NMR (270 MHz, CDCl₃) δ 0.75 (3H, s, 18-CH₃), 0.79 (3H, d, J = 6.2 Hz, 27-CH₃), 0.95 (3H, s, 19-CH₃), 0.96 (3H, d, J = 7.3 Hz, 21-CH₃), 1.0-2.05 (27H, complex m, aliphatic H) overlapping with 1.30 (3H, t, J = 7.3 Hz, CO₂-C-CH₃), 3.37 (1H, t, J = 11.0 Hz, 26-OCHH), 3.48 (1H, m, 26-OCHH), 4.17 (2H, q, J = 7.3 Hz, CO₂CH₂), 4.40 (1H, m, 16-OCH), 4.58 (1H, 7 line m, H-3) ppm; ¹³C NMR (67 MHz, CDCl₃) δ 14.3 (C-C-O₂C), 14.5 (C-21), 16.5 (C-18), 17.2 (C-27), 20.6 (C-11), 23.3 (C-19), 26.5, 26.6, 26.9, 28.8, 30.3, 31.4, 31.8, 32.1, 34.7, 35.0, 35.4, 40.2, 40.5, 40.6, 41.6, 41.8, 56.4 (C-14), 62.2 (C-17), 63.6 (C-O₂C), 66.8 (C-26), 77.9 (C-3), 80.9 (C-16), 109.2 (C-22), 154.6 (carbonyl) ppm; R_f 0.8 (silica, ethyl acetate-hexane, 1:4).

EXAMPLE 9

Synthesis of Episarsasapogenin Glycinate Hydrochloride

N-tert-butoxycarbonyl 5β,20α,22α,25S-spirostan-3α-yl glycinate (episarsasapogenin BOC glycinate)

Dicyclohexylcarbodiimide (0.68 g, 3.3 mmol) was added in portions over 1 min to a stirred mixture of episarsasapogenin (1.0 g, 2.4 mmol), *N-tert*-butoxycarbonylglycine (0.53 g, 3.0 mmol), 4-dimethylaminopyridine (10 mg, 0.1 mmol) and dry dichloromethane (20ml) at 0-5 °C. The mixture was stirred at room temperature overnight, filtered to remove dicyclohexylurea, and then partitioned between sodium hydrogen carbonate solution (1.5 g in 20 ml water) and dichloromethane (15 ml). The organic layer was separated, washed with 1N hydrochloric acid (15 ml) then water and dried over MgSO₄. The solvent was removed under vacuo to give an off-white foam. This material was triturated and stirred in ether (25 ml) for 3h. After standing overnight the mixture was filtered (to remove any residual dicyclohexylurea) and the filtrate evaporated to give an off-white solid (ca. 1.1 g). Recrystallisation from methanol (ca. 30 ml) afforded the BOC glycinate derivative as white microcrystals (0.40 g): mp 171-173°C; m/z 573.5 (M⁺ for C₃₄H₅₅NO₆) δ_H (270 MHz, CDCl₃) 0.76 (3H, s, 18-CH₃), 0.95 (3H, s, 19-CH₃), 0.99 (3H, d, J = 6.2 Hz, 21-CH₃), 1.08 (3H, d, J = 7.0 Hz, 27-CH₃), 1.1-2.1 (27H, complex m, aliphatic H) overlapping with 1.46

(9H, s, C(CH₃)₃), 3.30 (1H, brd, *J* = 11.0 Hz, 26-OCHH), 3.86 (2H, brd, *J* = 4.8 Hz, CH₂N), 3.95 (1H, dd, *J* = 11.0, 2.6 Hz, 26-OCHH), 4.42 (1H, m, 16-OCH), 4.79 (1H, 7 line m, H-3), 5.04 (1H, brs, NH). δ_c (270 MHz, CDCl₃) 14.3 (C-21), 16.1 (C-27), 16.5 (C-18), 20.7 (C-11), 23.3 (C-19), 25.8, 26.0, 26.6, 26.9, 27.1, 28.4, 31.8, 32.2, 34.7, 35.0, 35.5, 40.2, 40.6, 40.7, 41.9, 42.2, 42.8, 56.4 (C-14), 62.2 (C-17), 65.2 (C-26), 75.6 (C-3), 79.9 (CH₂N), 81.0 (C-16), 109.7 (C-22), 155.7 (carbamate carbonyl), 169.8 (ester carbonyl) *R_f* 0.4 (silica, ethyl acetate-hexane, 1:8)

10 *5 β ,20 α ,22 α ,25S*-spirostan-3 α -yl glycinate Hydrochloride (*Episarsasapogenin Glycinate Hydrochloride*)

A slow steady stream of hydrogen chloride was passed through a stirred solution of *N*-*tert*-butoxycarbonyl 5 β ,20 α ,22 α ,25*S*-spirostan-3 α -yl glycinate (0.40 g, 0.78 mmol) in dry ethyl acetate-ether (24 ml of 1:8) at 0-5 °C with exclusion of moisture. After ca. 45 min the reaction mixture was saturated (excess gas discharging into a trap) and the hydrogen chloride supply disconnected. Stirring was continued and the mixture allowed to warm to room temperature. TLC studies indicated that the deprotection reaction was complete after ca. 2-3h. The resulting white suspension was allowed to stand for 3h, and the powdery white solid removed by filtration and washed with ether. This material was air-dried and then further dried in a vacuum dessicator over CaCl₂ to constant weight to give 0.24 g of a free-flowing white microcrystalline solid, mp 270-272 °C (decomp.) *m/z* 473 (*M*⁺ for C₂₉H₄₇NO₄) HCl salt *M* = 510.2 δ_H (270 MHz, CDCl₃) 0.76 (3H, s, 18-CH₃), 0.95 (3H, s, 19-CH₃), 0.99 (3H, d, *J* = 6.2 Hz, 21-CH₃), 1.08 (3H, d, *J* = 7.0 Hz, 27-CH₃), 1.1-2.1 (27H, complex m, aliphatic H) overlapping with 1.46 (9H, s, C(CH₃)₃), 3.30 (1H, brd, *J* = 11.0 Hz, 26-OCHH), 3.86 (2H, brd, *J* = 4.8 Hz, CH₂N), 3.95 (1H, dd, *J* = 11.0, 2.6 Hz, 26-OCHH), 4.42 (1H, m, 16-OCH), 4.79 (1H, 7 line m, H-3), 5.04 (1H, brs, NH). δ_c (270 MHz, CDCl₃) 14.3 (C-21), 16.1 (C-27), 16.5 (C-18), 20.7 (C-11), 23.3 (C-19), 25.8, 26.0, 26.6, 26.9, 27.1, 28.4, 31.8, 32.2, 34.7, 35.0, 35.5, 40.2, 40.6, 40.7, 41.9, 42.2, 42.8, 56.4 (C-14), 62.2 (C-17), 65.2 (C-26), 75.6 (C-3), 79.9 (CH₂N), 81.0 (C-16), 109.7 (C-22), 155.7 (carbamate carbonyl), 169.8 (ester carbonyl) *R_f* 0.6 (silica, dichloromethane-methanol-0.88 ammonia, 9:1:0.1)

EXAMPLE 10

Synthesis of Sarsasapogenin Glycinate Hydrochloride

The title compound was made by a synthesis analogous to that of Example 9, using instead sarsasapogenin as starting material.

The intermediate, N-tert-butoxycarbonyl 5 β ,20 α ,22 α ,25S-spirostan-3 β -yl glycinate (Sarsasapogenin BOC Glycinate) was obtained as white microcrystals, m/z 573.5 (M^+ for C₃₄H₅₅NO₆) R_f 0.45 (silica, ethyl acetate-hexane, 1:4), and the title compound was obtained as a free-flowing white microcrystalline solid, mp 259-261 °C (decomp.) m/z 473 (M^+ for C₂₉H₄₇NO₄) HCl salt M = 510.2 R_f 0.5 (silica, dichloromethane-methanol-0.88 ammonia, 12:1:0.1)

EXAMPLE 11

Synthesis of Epismilagenin Glycinate Hydrochloride

The title compound was synthesised by a method analogous to that of Example 9, using instead epismilagenin as starting material.

The intermediate, N-tert-butoxycarbonyl 5 β ,20 α ,22 α ,25R-spirostan-3 α -yl glycinate (Epismilagenin BOC Glycinate), was obtained as white microcrystals, mp 100-103 °C m/z 573.5 (M^+ for C₃₄H₅₅NO₆) δ_H (500 MHz, CDCl₃) 0.75 (3H, s, 18-CH₃), 0.79 (3H, d, J = 6.3 Hz, 27-CH₃), 0.95 (3H, s, 19-CH₃), 0.96 (3H, d, J = 6.9 Hz, 21-CH₃), 1.0-2.0 (27H, complex m, aliphatic H) overlapping with 1.45 (9H, s, C(CH₃)₃), 3.37 (1H, t, J = 10.9 Hz, 26-OCHH), 3.47 (1H, m, 26-OCHH), 3.87 (2H, J = 5.3 Hz, CH₂N), 4.40 (1H, m, 16-OCH), 4.79 (1H, 7 line m, H-3), 5.04 (1H, br peak, NH). δ_C (270 MHz, CDCl₃) 14.7 (C-21), 16.6 (C-18), 17.3 (C-27), 20.8 (C-11), 23.5 (C-19), 26.7, 26.8, 27.1, 28.5, 29.0, 30.5, 31.6, 32.0, 32.3, 34.9, 35.2, 35.6, 40.4, 40.7, 40.8, 41.8, 42.0, 42.9, 56.5 (C-14), 62.4 (C-17), 67.0 (C-26), 75.7 (C-3), 80.1 (CO₂C), 81.1 (C-16), 109.4 (C-22), 155.9 (carbamate carbonyl), 170.0 (ester carbonyl) R_f 0.46 (silica, ethyl acetate-hexane, 1:4)

The title compound was obtained as a free-flowing white microcrystalline solid, mp 273-275 °C (decomp.) m/z 473 (M^+ for C₂₉H₄₇NO₄) HCl salt M = 510.2; δ_H [500 MHz, (CD₃)₂SO] 0.71 (3H, s, 18-CH₃), 0.75 (3H, d, J = 6.3 Hz, 27-CH₃), 0.91 (3H, d, J = 6.9 Hz, 21-CH₃), 0.92 (3H, s, 19-CH₃), 1.0-2.0 (27H, complex m, aliphatic H), 3.20 (1H, t, J = 11.1 Hz, 26-OCHH), 3.41 (1H, m, 26-OCHH), 3.71 (2H, brs, CH₂N), 4.28 (1H, m, 16-OCH), 4.75 (1H, 7 line m, H-3), 8.54 (3H, s, NH₃). δ_C [125 MHz, (CD₃)₂SO] 14.6 (C-21), 16.1 (C-18), 17.0 (C-27),

20.1 (C-11), 22.9 (C-19), 26.0, 26.2, 26.4, 28.5, 29.7, 30.9, 31.4, 31.6, 34.2, 34.3, 34.9, 41.0, 41.1, 55.5 (C-14), 61.9 (C-17), 65.9 (C-26), 75.4 (C-3), 80.2 (C-16), 108.3 (C-22), 166.9 (carbonyl). R_f 0.5 (silica, dichloromethane-methanol-0.88 ammonia, 12:1:0.1)

5 EXAMPLE 12

Synthesis of Epismilagenin L-Alaninate Hydrochloride

10 The title compound was synthesised by a method analogous to that of Example 9, using instead epismilagenin and *N*-*tert*-butoxycarbonyl-L-alanine as starting materials.

The intermediate, *N*-*tert*-butoxycarbonyl 5 β ,20 α ,22 α ,25R-spirostan-3 α -yl L-alaninate (Epismilagenin BOC L-Alaninate), was obtained as white microcrystals, mp 171-173 °C m/z 587.5 (M^+ for $C_{35}H_{57}NO_6$) δ_H (500 MHz, $CDCl_3$) 0.76 (3H, s, 18-CH₃), 0.79 (3H, d, J = 6.4 Hz, 27-CH₃), 0.95 (3H, s, 19-CH₃), 0.97 (3H, d, J = 7.0 Hz, 21-CH₃), 1.0-2.03 (27H, complex m, aliphatic H) overlapping with 1.37 (3H, d, J = 7.1 Hz) and 1.45 (9H, s, C(CH₃)₃), 3.38 (1H, t, J = 10.9 Hz, 26-OCHH), 3.47 (1H, m, 26-OCHH), 4.25 (1H, m, CHN), 4.40 (1H, m, 16-OCH), 4.76 (1H, 7 line m, H-3), 5.06 (1H, br d, J = 5.7 Hz, NH). δ_c (125 MHz, $CDCl_3$) 14.7 (C-21), 16.6 (C-18), 17.3 (C-27), 19.0 (CH₃-C-N), 20.8 (C-11), 23.5 (C-19), 26.7, 26.8, 27.1, 28.5, 29.0, 30.5, 31.6, 32.0, 32.3, 34.9, 35.2, 35.6, 40.4, 40.7, 40.9, 41.8, 42.0, 49.6, 56.5 (C-14), 62.5 (C-17), 67.0 (C-26), 75.5 (C-3), 79.9 (CO₂C), 81.1 (C-16), 109.4 (C-22), 155.3 (carbamate carbonyl), 173.1 (ester carbonyl) R_f 0.53 (silica, ethyl acetate-hexane, 1:4)

25 The title compound was obtained as a free-flowing white microcrystalline solid, mp 233-235 °C (decomp.) m/z 487 (M^+ for $C_{30}H_{49}NO_4$) HCl salt M = 524.2 δ_H [500 MHz, $(CD_3)_2SO$] 0.71 (3H, s, 18-CH₃), 0.74 (3H, d, J = 6.3 Hz, 27-CH₃), 0.90 (3H, d, J = 6.9 Hz, 21-CH₃), 0.92 (3H, s, 19-CH₃), 1.0-1.95 (27H, complex m, aliphatic H) overlapping with 1.42 (3H, d, J = 7.2 Hz, CH₃-C-N), 3.21 (1H, t, J = 11.0 Hz, 26-OCHH), 3.41 (1H, m, 26-OCHH), 3.96 (1H, q, J = 7.0 Hz, CHN), 4.29 (1H, m, 16-OCH), 4.73 (1H, 7 line m, H-3), 8.66 (3H, s, NH₃). δ_c [125 MHz, $(CD_3)_2SO$] 14.5 (C-21), 15.6 (Ala Me), 16.0 (C-18), 17.0 (C-27), 20.1 (C-11), 22.8 (C-19), 25.9, 26.1, 26.4, 28.4, 29.7, 30.9, 31.3, 31.5, 34.2, 34.9, 40.9, 41.0, 47.8, 55.5 (C-14), 61.9 (C-17), 65.8 (C-26), 75.4 (C-3), 80.2 (C-16), 108.2 (C-22), 169.3 (carbonyl). Four signals not detected, probably hidden under solvent peaks. R_f 0.56 (silica, dichloromethane-methanol-0.88 ammonia, 12:1:0.1)

EXAMPLE 13**Synthesis of Epismilagenin L-Valinate Hydrochloride**

- 5 The title compound was synthesised by a method analogous to that of Example 9, using instead epismilagenin and N-*tert*-butoxycarbonyl-L-valine as starting materials.

The intermediate, N-*tert*-butoxycarbonyl 5 β ,20 α ,22 α ,25R-spirostan-3 α -yl L-valinate (Epismilagenin BOC L-Valinate) was obtained as white microcrystals, mp 68-71 °C m/z 615.5 (M⁺ for C₃₇H₆₁NO₆) δ_H (500 MHz, CDCl₃) 0.76 (3H, s, 18-CH₃), 0.79 (3H, d, J = 6.4 Hz, 27-CH₃), 0.89 (6H, d, J = 6.9 Hz, C(CH₃)₂), 0.95 (3H, s, 19-CH₃), 0.96 (3H, d, J = 6.9 Hz, 21-CH₃), 1.0-2.2 (28H, complex m, aliphatic H) overlapping with 1.43, 1.45 (9H, 2 x s, C(CH₃)₃), 3.38 (1H, t, J = 10.9 Hz, 26-OCHH), 3.47 (1H, m, 26-OCHH), 4.17 (1H, dd, J = 9.9, 4.1 Hz, CHN), 4.40 (1H, m, 16-OCH), 4.79 (1H, 7 line m, H-3), 5.01 (1H, br t, J = 9.9 Hz, NH). δ_C (125 MHz, CDCl₃) 14.7 (C-21), 16.6 (C-18), 17.3 (C-27), 17.7 (Val Me), 19.2 (Val Me), 20.8 (C-11), 23.5 (C-19), 26.7, 26.9, 27.1, 28.5 (t-butyl Me), 29.0, 30.5, 31.6, 32.0, 32.4, 34.9, 35.2, 35.7, 40.4, 40.7, 40.9, 41.8, 42.0, 56.4 (C-14), 58.8 (CHN), 62.5 (C-17), 67.1 (C-26), 75.4 (C-3), 79.8 (CO₂C), 81.1 (C-16), 109.4 (C-22), 155.9 (carbamate carbonyl), 172.1 (ester carbonyl) R_f 0.60 (silica, ethyl acetate-hexane, 1:4)

20

The title compound was obtained as a free-flowing white microcrystalline solid, mp 171-173 °C (decomp.) m/z 515.7 (M⁺ for C₃₂H₅₃NO₄) HCl salt M = 552.2; δ_H [500 MHz, (CD₃)₂SO] 0.71 (3H, s, 18-CH₃), 0.74 (3H, d, J = 6.4 Hz, 27-CH₃), 0.90 (3H, d, J = 6.9 Hz, 21-CH₃), 0.93 (3H, s, 19-CH₃), 0.95 (3H, d, J = 6.9 Hz, Valine -CH₃), 1.00 (3H, d, J = 6.9 Hz, Valine-CH₃), 1.01-2.0 (27H, complex m, aliphatic H), 2.22 (1H, m, CH-C-N), 3.21 (1H, t, J = 11.0 Hz, 26-OCHH), 3.41 (1H, m, 26-OCHH), 3.75 (1H, m, CHN), 4.28 (1H, m, 16-OCH), 4.77 (1H, 7 line m, H-3), 8.6 (3H, br peak, NH₃). δ_C [125 MHz, (CD₃)₂SO] 14.5 (C-21), 16.0 (C-18), 17.0 (C-27), 17.4 (Val Me), 18.4 (Val Me), 20.1 (C-11), 22.9 (C-19), 26.1, 26.2, 26.4, 28.4 (t-Bu), 29.2, 29.7, 30.9, 31.3, 31.7, 34.2, 34.9, 41.0, 41.1, 55.5 (C-14), 57.1 (CHN), 61.9 (C-17), 65.8 (C-26), 75.4 (C-3), 80.2 (C-16), 108.3 (C-22), 168.0 (carbonyl). Four signals not detected, probably hidden under solvent peaks. R_f 0.64 (silica, dichloromethane-methanol-0.88 ammonia, 12:1:0.1)

35

EXAMPLE 14**Synthesis of Epismilagenin L-Isoleucinate Hydrochloride**

- 5 The title compound was synthesised by a method analogous to that of Example 9, using instead epismilagenin and N-tert-butoxycarbonyl-L-isoleucine as starting materials.

The intermediate, N-tert-butoxycarbonyl 5 β ,20 α ,22 α ,25R-spirostan-3 α -yl L-isoleucinate (Epismilagenin BOC L-Isoleucinate), was obtained as white microcrystals, mp 67-70 °C
 10 m/z 629.5 (M⁺ for C₃₈H₆₃NO₆) R_f 0.6 (silica, ethyl acetate-hexane, 1:4)

The title compound was obtained as a free-flowing white microcrystalline solid, mp 169-171 °C (decomp.) m/z 529.7 (M⁺ for C₃₃H₅₅NO₄) HCl salt M = 566.2 R_f 0.7 (silica, dichloromethane-methanol-0.88 ammonia, 12:1:0.1)

15

EXAMPLE 15**Synthesis of Epismilagenin L-Phenylalaninate Hydrochloride**

- 20 The title compound was synthesised by a method analogous to that of Example 9, using instead epismilagenin and N-tert-butoxycarbonyl-L-phenylalanine as starting materials.

The intermediate, N-tert-butoxycarbonyl 5 β ,20 α ,22 α ,25R-spirostan-3 α -yl L-phenylalaninate (Epismilagenin BOC L-Phenylalaninate), was obtained as white microcrystals, mp 66-68 °C
 25 m/z 663.5 (M⁺ for C₄₁H₆₁NO₆) R_f 0.6 (silica, ethyl acetate-hexane, 1:5).

The title compound was obtained as a free-flowing white microcrystalline solid, mp 254-256 °C (decomp.) m/z 563.5 (M⁺ for C₃₆H₅₃NO₄) HCl salt M = 600.2 R_f 0.6 (silica, dichloromethane-methanol-0.88 ammonia, 12:1:0.1)

30

EXAMPLE 16**Synthesis of Epismilagenin L-Methioninate Hydrochloride**


The title compound was synthesised by a method analogous to that of Example 9, using instead epismilagenin and N-*tert*-butoxycarbonyl-L-methionine as starting materials.

5 The intermediate, N-*tert*-butoxycarbonyl 5 β ,20 α ,22 α ,25R-spirostan-3 α -yl L-methioninate (Epismilagenin BOC L-Methioninate), was obtained as white microcrystals, mp 76-79 °C
m/z 647.9 (M^+ for $C_{37}H_{61}NO_6S$) R_f 0.5 (silica, ethyl acetate-hexane, 1:5)

10 The title compound was obtained as a free-flowing white microcrystalline solid, mp 173-176 °C (decomp.) m/z 547.8 (M^+ for $C_{32}H_{53}NO_4S$) HCl salt $M = 584.3$ R_f 0.5 (silica, dichloromethane-methanol-0.88 ammonia, 12:1:0.1)

CLAIMS:

1. Use of compounds of the general formula II:



wherein the group R is selected from hydrogen; alkylcarbonyl; or alkoxy carbonyl;
wherein any alkyl group is optionally substituted with aryl, amino, mono- or di-alkyl-
amino, a carboxylic acid residue (-COOH), or any combination thereof;

including all stereoisomers and racemic mixtures thereof, and their pharmaceutically
acceptable salts,

in the treatment or prevention of, or in the preparation of compositions for the
treatment or prevention of, (i) non-cognitive neurodegeneration, (ii) non-cognitive
neuromuscular degeneration, or (iii) receptor loss in the absence of cognitive, neural
and neuromuscular impairment, in human and non-human animals suffering
therefrom or susceptible thereto.

2. A use according to claim 1, wherein the compound of formula II is selected from:

sarsasapogenin

sarsasapogenin cathylate

sarsasapogenin acetate

sarsasapogenin succinate and pharmaceutically acceptable salts thereof

episarsasapogenin

episarsasapogenin cathylate

episarsasapogenin acetate

episarsasapogenin succinate and pharmaceutically acceptable salts thereof

smilagenin

smilagenin cathylate

smilagenin acetate

smilagenin succinate and pharmaceutically acceptable salts thereof

epismilagenin

epismilagenin cathylate

5 epismilagenin acetate

epismilagenin succinate and pharmaceutically acceptable salts thereof

3. A use according to claim 1, wherein the compound of formula II is selected from:

10 sarsasapogenin glycinate and pharmaceutically acceptable salts thereof
 episarsasapogenin glycinate and pharmaceutically acceptable salts thereof
 smilagenin glycinate and pharmaceutically acceptable salts thereof
 epismilagenin glycinate and pharmaceutically acceptable salts thereof
 sarsasapogenin alaninate and pharmaceutically acceptable salts thereof
 episarsasapogenin alaninate and pharmaceutically acceptable salts thereof
 15 smilagenin alaninate and pharmaceutically acceptable salts thereof
 epismilagenin alaninate and pharmaceutically acceptable salts thereof
 sarsasapogenin valinate and pharmaceutically acceptable salts thereof
 episarsasapogenin valinate and pharmaceutically acceptable salts thereof
 smilagenin valinate and pharmaceutically acceptable salts thereof
 20 epismilagenin valinate and pharmaceutically acceptable salts thereof
 sarsasapogenin phenylalaninate and pharmaceutically acceptable salts thereof
 episarsasapogenin phenylalaninate and pharmaceutically acceptable salts thereof
 smilagenin phenylalaninate and pharmaceutically acceptable salts thereof
 epismilagenin phenylalaninate and pharmaceutically acceptable salts thereof
 25 sarsasapogenin isoleucinate and pharmaceutically acceptable salts thereof
 episarsasapogenin isoleucinate and pharmaceutically acceptable salts thereof
 smilagenin isoleucinate and pharmaceutically acceptable salts thereof
 epismilagenin isoleucinate and pharmaceutically acceptable salts thereof
 sarsasapogenin methioninate and pharmaceutically acceptable salts thereof
 30 episarsasapogenin methioninate and pharmaceutically acceptable salts thereof
 smilagenin methioninate and pharmaceutically acceptable salts thereof
 epismilagenin methioninate and pharmaceutically acceptable salts thereof.

4. Use of compounds of the general formula II as defined in claim 1,

35 provided that: R is not hydrogen or unsubstituted acetyl unless simultaneously the stereochemistry of C3 is α and of C25 is S; R is not unsubstituted ethoxycarbonyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is R; and R is not

succinyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is S or the stereochemistry of C3 is R(α) and of C25 is R;

including, subject to the provisos set out above, all stereoisomers and racemic mixtures thereof, and their pharmaceutically acceptable salts,

in the treatment or prevention of, or in the preparation of compositions for the treatment or prevention of, cognitive dysfunction in human and non-human animals suffering therefrom or susceptible thereto.

5. Use according to claim 4, wherein the compound of formula II is selected from:
 - sarsasapogenin cathylate
 - episarsasapogenin
 - episarsasapogenin cathylate
 - episarsasapogenin acetate
 - episarsasapogenin succinate and pharmaceutically acceptable salts thereof
 - epismilagenin cathylate
 - sarsasapogenin glycinate and pharmaceutically acceptable salts thereof
 - episarsasapogenin glycinate and pharmaceutically acceptable salts thereof
 - smilagenin glycinate and pharmaceutically acceptable salts thereof
 - epismilagenin glycinate and pharmaceutically acceptable salts thereof
 - sarsasapogenin alaninate and pharmaceutically acceptable salts thereof
 - episarsasapogenin alaninate and pharmaceutically acceptable salts thereof
 - smilagenin alaninate and pharmaceutically acceptable salts thereof
 - epismilagenin alaninate and pharmaceutically acceptable salts thereof
 - sarsasapogenin valinate and pharmaceutically acceptable salts thereof
 - episarsasapogenin valinate and pharmaceutically acceptable salts thereof
 - smilagenin valinate and pharmaceutically acceptable salts thereof
 - epismilagenin valinate and pharmaceutically acceptable salts thereof
 - sarsasapogenin phenylalaninate and pharmaceutically acceptable salts thereof
 - episarsasapogenin phenylalaninate and pharmaceutically acceptable salts thereof
 - smilagenin phenylalaninate and pharmaceutically acceptable salts thereof
 - epismilagenin phenylalaninate and pharmaceutically acceptable salts thereof
 - sarsasapogenin isoleucinate and pharmaceutically acceptable salts thereof
 - episarsasapogenin isoleucinate and pharmaceutically acceptable salts thereof
 - smilagenin isoleucinate and pharmaceutically acceptable salts thereof

epismilagenin isoleucinate and pharmaceutically acceptable salts thereof
 sarsasapogenin methioninate and pharmaceutically acceptable salts thereof
 episarsasapogenin methioninate and pharmaceutically acceptable salts thereof
 smilagenin methioninate and pharmaceutically acceptable salts thereof
 5 epismilagenin methioninate and pharmaceutically acceptable salts thereof.

6. Use according to any one of claims 1 to 5, wherein the active agent has the C₂₅
 methyl group in the R configuration.

10 7. Use according to any one of claims 1 to 5, wherein the active agent has the C₂₅
 methyl group in the S configuration.

8. Compounds of the general formula II as defined in claim 1, wherein the group R is
 selected from alkylcarbonyl; or alkoxycarbonyl; wherein any alkyl group is optionally
 15 substituted with aryl, amino, alkoxycarbonylamino, mono-alkyl-amino, di-alkyl-
 amino, N-alkyl,N-alkoxycarbonyl-amino, or a carboxylic acid residue (-COOH), or
 any combination thereof; provided that:

20 R is not unsubstituted acetyl unless simultaneously the stereochemistry of C3 is α and
 of C25 is S;

R is not unsubstituted ethoxycarbonyl when simultaneously the stereochemistry of C3
 is S(β) and of C25 is R;

25 R is not succinyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is
 S or the stereochemistry of C3 is R(α) or S(β) and of C25 is R; and

30 R is not propionyl, butyryl, valeryl, isovaleryl, caproyl, isocaproyl, diethylacetyl,
 octanoyl, decanoyl, lauryl, myristyl, palmityl, stearyl, benzoyl, phenylacetyl,
 phenylpropionate, cinnamate, p-nitrobenzoate, 3,5-dinitrobenzoate, p-chlorobenzoate,
 2,4-dichlorobenzoyl, p-bromobenzoyl, m-bromobenzoyl, p-methoxybenzoyl, furoyl,
 phthalyl when the stereochemistry of C25 is R and the stereochemistry of C3 is S(β);

35 including, subject to the provisos set out above, all stereoisomers and racemic
 mixtures thereof, and salts thereof.

9. Compounds of formula II as defined in claim 1, wherein the group R is selected from lower alkylcarbonyl and lower alkoxy carbonyl, optionally substituted with a terminal carboxylic acid (-COOH) residue.

5 10. Compounds as claimed in claim 8 or 9, wherein the C₂₅ methyl group is in the R configuration.

11. Compounds as claimed in claim 8 or 9, wherein the C₂₅ methyl group is in the S configuration.

10

12. A compound selected from epismilagenin cathylate, sarsasapogenin cathylate, episarsasapogenin cathylate, episarsasapogenin acetate, episarsasapogenin succinate, sarsasapogenin glycinate, episarsasapogenin glycinate, smilagenin glycinate, epismilagenin glycinate, sarsasapogenin alaninate, episarsasapogenin alaninate, 15 smilagenin alaninate, epismilagenin alaninate, sarsasapogenin valinate, episarsasapogenin valinate, smilagenin valinate, epismilagenin valinate, sarsasapogenin phenylalaninate, episarsasapogenin phenylalaninate, smilagenin phenylalaninate, epismilagenin phenylalaninate, sarsasapogenin isoleucinate, episarsasapogenin isoleucinate, smilagenin isoleucinate, epismilagenin isoleucinate, 20 sarsasapogenin methioninate, episarsasapogenin methioninate, smilagenin methioninate, epismilagenin methioninate and pharmaceutically acceptable salts thereof.

20

13. Compounds according to any one of claims 8 to 12, for use as a medicament:

25

14. A method of synthesising compounds of formula II, other than those with R = H, which comprises reacting a compound of formula II in which R = H with a compound of formula

30



in which R is selected from alkylcarbonyl; or alkoxy carbonyl; wherein any alkyl group is optionally substituted with aryl, amino, mono-alkyl-amino, di-alkyl-amino, a carboxylic acid residue (-COOH), or any combination thereof; and L is a leaving 35 group, under conditions suitable for nucleophilic substitution.

15. A method according to claim 14, wherein the compound L-R is a carboxylic acid, an anhydride, or an acyl halide.
- 5 16. A method of synthesising a steroidal sapogenin derivative, which comprises treating a selected steroidal sapogenin with ethylchloroformate in the presence of a base to form the 3-ethoxycarbonyl derivative.
- 10 17. A method according to claim 16, wherein said base consists of dry pyridine dissolved in dry dichloromethane.
18. The synthesis of epismilagenin cathylate from epismilagenin by reaction with ethylchloroformate or related reagent and a base.
- 15 19. The synthesis of sarsasapogenin cathylate from sarsasapogenin by reaction with ethylchloroformate or related reagent and a base.
- 20 20. The synthesis of episarsasapogenin cathylate from episarsasapogenin by reaction with ethylchloroformate or related reagent and a base.
21. The synthesis of episarsasapogenin succinate from episarsasapogenin by reaction with succinic anhydride or related reagent and a base.
- 25 22. The use of a compound as claimed in any one of claims 9 to 12 or a medicinally acceptable salt thereof in the manufacture of a medicament for increasing the receptor number or turnover, or enhancing the function of receptors, in a human or non-human animal.
- 30 23. A composition having activity against non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, or receptor loss in the absence of cognitive, neural or neuromuscular impairment, in a human or non-human animal, which comprises an effective amount of a compound of general formula II as defined in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof.
- 35 24. A composition having activity against cognitive dysfunction in a human or non-human animal, which comprises an effective dosage of a compound of general formula II as defined in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof; provided that: R is not hydrogen or unsubstituted acetyl unless

simultaneously the stereochemistry of C3 is α and of C25 is S; R is not unsubstituted ethoxycarbonyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is R; and R is not succinyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is S or the stereochemistry of C3 is R(α) and of C25 is R.

5

25. A pharmaceutical composition which comprises a pharmacologically effective amount of one or more compound of formula II as defined in any one of claims 8 to 12, or a pharmaceutically acceptable salt thereof.

10

26. A foodstuff, food supplement or beverage which comprises a pharmacologically effective amount of one or more compound of formula II as defined in any one of claims 8 to 12, or a pharmaceutically acceptable salt thereof.

15

27. A composition having cognitive function enhancing properties which comprises a pharmacologically effective amount of one or more of epismilagenin cathylate, sarsasapogenin cathylate, episarsasapogenin cathylate, episarsasapogenin acetate, episarsasapogenin succinate, sarsasapogenin glycinate, episarsasapogenin glycinate, smilagenin glycinate, epismilagenin glycinate, sarsasapogenin alaninate, episarsasapogenin alaninate, smilagenin alaninate, epismilagenin alaninate, sarsasapogenin valinate, episarsasapogenin valinate, smilagenin valinate, epismilagenin valinate, sarsasapogenin phenylalaninate, episarsasapogenin phenylalaninate, smilagenin phenylalaninate, epismilagenin phenylalaninate, sarsasapogenin isoleucinate, episarsasapogenin isoleucinate, smilagenin isoleucinate, epismilagenin isoleucinate, sarsasapogenin methioninate, episarsasapogenin methioninate, smilagenin methioninate, epismilagenin methioninate or of a pharmaceutically acceptable salt thereof.

25

28. A medicament containing one or more of epismilagenin cathylate, sarsasapogenin cathylate, episarsasapogenin cathylate, episarsasapogenin acetate, episarsasapogenin succinate, sarsasapogenin glycinate, episarsasapogenin glycinate, smilagenin glycinate, epismilagenin glycinate, sarsasapogenin alaninate, episarsasapogenin alaninate, smilagenin alaninate, epismilagenin alaninate, sarsasapogenin valinate, episarsasapogenin valinate, smilagenin valinate, epismilagenin valinate, sarsasapogenin phenylalaninate, episarsasapogenin phenylalaninate, smilagenin phenylalaninate, epismilagenin phenylalaninate, sarsasapogenin isoleucinate, episarsasapogenin isoleucinate, smilagenin isoleucinate, epismilagenin isoleucinate, sarsasapogenin methioninate, episarsasapogenin methioninate, smilagenin

30

35

methioninate, epismilagenin methioninate or of a pharmaceutically acceptable salt thereof.

29. A method for treating or preventing non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, or receptor loss in the absence of cognitive, neural or neuromuscular impairment, in a human or non-human animal in need thereof, which comprises administering to the said human or non-human animal an effective dosage of a compound of general formula II as defined in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof.
30. A method for treating or preventing cognitive dysfunction in a human or non-human animal in need thereof, which comprises administering to the said human or non-human animal an effective dosage of a compound of general formula II as defined in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof; provided that: R is not hydrogen or unsubstituted acetyl unless simultaneously the stereochemistry of C3 is α and of C25 is S; R is not unsubstituted ethoxycarbonyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is R; and R is not succinnyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is S or the stereochemistry of C3 is R(α) and of C25 is R.
31. A method for the treatment of cognitive dysfunction in a patient suffering from one of: Alzheimer's disease, SDAT, AAMI, Lewi body dementia or autism, which method comprises administering to the patient a pharmacologically effective amount of a compound of formula II as defined in any one of claims 1 to 12, or of a pharmaceutically acceptable salt thereof; provided that: R is not hydrogen or unsubstituted acetyl unless simultaneously the stereochemistry of C3 is α and of C25 is S; R is not unsubstituted ethoxycarbonyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is R; and R is not succinnyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is S or the stereochemistry of C3 is R(α) and of C25 is R.
32. A method for enhancing cognitive function in a human or non-human animal, which method comprises administering to the patient an effective amount of a compound of formula II as defined in any one of claims 1 to 12, or of a pharmaceutically acceptable salt thereof; provided that: R is not hydrogen or unsubstituted acetyl unless simultaneously the stereochemistry of C3 is α and of C25 is S; R is not unsubstituted ethoxycarbonyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is

R; and R is not succinyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is S or the stereochemistry of C3 is R(α) and of C25 is R.

33. A method according to claim 32, wherein the treatment is a non-therapeutic method practiced on a normal subject, for enhancing the subject's cognitive function.
34. A method for the treatment of (i) non-cognitive neurodegeneration, (ii) non-cognitive neuromuscular degeneration, or (iii) receptor loss in the absence of cognitive, neural or neuromuscular impairment, in a human or non-human animal in a patient suffering from one of: Parkinson's disease, muscular dystrophy including facioscapulohumeral muscular dystrophy (FSH), Duchenne muscular dystrophy, Becker muscular dystrophy and Bruce's muscular dystrophy, Fuchs' dystrophy, myotonic dystrophy, corneal dystrophy, reflex sympathetic dystrophy syndrome (RSDSA), neurovascular dystrophy, myasthenia gravis, Lambert Eaton disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, postural hypotension, chronic fatigue syndrome, asthma, susceptibility to heart failure, and macular degeneration, which method comprises administering to the patient a pharmacologically effective amount of a compound of formula II as defined in any one of claims 1 to 12, or of a pharmaceutically acceptable salt thereof.
35. Use of one or more compound of formula II as defined in any one of claims 1 to 12, or of a pharmaceutically acceptable salt thereof as an ingredient in a pharmaceutical composition, food product, food supplement or beverage in a method for the treatment of Parkinson's disease, muscular dystrophy including facioscapulohumeral muscular dystrophy (FSH), Duchenne muscular dystrophy, Becker muscular dystrophy and Bruce's muscular dystrophy, Fuchs' dystrophy, myotonic dystrophy, corneal dystrophy, reflex sympathetic dystrophy syndrome (RSDSA), neurovascular dystrophy, myasthenia gravis, Lambert Eaton disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, postural hypotension, chronic fatigue syndrome, asthma, susceptibility to heart failure, and macular degeneration.
36. Use of one or more compound of formula II as defined in any one of claims 1 to 12, or of a pharmaceutically acceptable salt thereof provided that: R is not hydrogen or unsubstituted acetyl unless simultaneously the stereochemistry of C3 is α and of C25 is S; R is not unsubstituted ethoxycarbonyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is R; and R is not succinyl when simultaneously the stereochemistry of C3 is S(β) and of C25 is S or the stereochemistry of C3 is R(α)

and of C25 is R; as an ingredient in a pharmaceutical composition, food product, food supplement or beverage in a method for the treatment of Alzheimer's disease, SDAT, AAMI, MCI and autism.

- 5 37. A method of enhancing cognitive function in a patient suffering from age-related cognitive dysfunction, which comprises administering to the patient a pharmacologically effective dose of a compound as defined in any one of claims 1 to 12.
- 10 38. A method as claimed in claim 30, 31, 32 or 36, which is for the treatment of Alzheimer's disease or a senile dementia of the Alzheimer's type.
- 15 39. A method for the treatment of one of: Parkinson's disease, Lewi body dementia, postural hypotension, autism, chronic fatigue syndrome, myasthenia gravis, Lambert Eaton disease, Huntington disease, multiple sclerosis, asthma, heart failure, epilepsy, and diseases and problems associated with ageing, which method comprises administering to a patient a pharmacologically effective amount of a compound as defined in any one of claims 9 to 12 including a pharmaceutically acceptable salt thereof.
- 20 40. A method for the treatment of one of: Parkinson's disease, Lewi body dementia, postural hypotension, autism, chronic fatigue syndrome, myasthenia gravis, Lambert Eaton disease, Huntington disease, multiple sclerosis, asthma, heart failure, epilepsy, and diseases and problems associated with ageing, which method comprises administering to a patient a pharmacologically effective amount of sarsasapogenin.
- 25 41. A method as claimed in claim 40, wherein the sarsasapogenin is in the form of a plant extract, or dry powdered plant material, derived from a plant of the genus Smilax, Asparagus, Anemarrhena, Dioscorea, Yucca or Agave.
- 30 42. A method according to claim 40 or 41, which comprises administering a foodstuff or beverage containing an effective dosage of sarsasapogenin.
- 35 43. The use of sarsasapogenin as an ingredient in a food product or beverage in a method for the treatment of Parkinson's disease, Lewi body dementia, postural hypotension, autism, chronic fatigue syndrome, myasthenia gravis, Lambert Eaton disease,

Huntington disease, multiple sclerosis, asthma, heart failure, epilepsy, and diseases and problems associated with ageing.



ABSTRACT**SAPOGENIN DERIVATIVES. THEIR SYNTHESIS AND USE, AND METHODS
BASED UPON THEIR USE**

5



The invention discloses certain steroidal sapogenins and derivatives thereof, and their use in the treatment of cognitive dysfunction, non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, and receptor loss in the absence of cognitive, neural and neuromuscular impairment. Methods of synthesis, treatment and pharmaceutical compositions are also disclosed.


10



Figure 2Figure 3

3/3

Figure 4Figure 5



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.